Hetero-aromatic ring substituted phenyloxazolidinone antimicrobials

ABSTRACT

A hetero-aromatic (Q) substituted phenyloxazolidinone antimicrobial of Formula (I) wherein Q is a 5-member hetero-aromatic having from one to four nitrogen atoms or alternatively a benzoannulated 5-member hetero-aromatic having from one to four nitrogen atoms where R 1  is independently H, OCH 3 , F, or Cl; R 2  is hydrogen, C 1  -C 8  alkyl (optionally substituted with one or more of F, Cl, hydroxy, C 1  -C 8  alkoxy, C 1  -C 8  acyloxy), C 3  -C 6  cycloalkyl, amino, C 1  -C 8  alkylamino, C 1  -C 8  dialkylamino, C 1  -C 8  alkoxy; and each Q is optionally substituted with one or more of H, F, Cl, Br, OR 4 , SR 4 , S(O) n  R 4  (n=1 or 2), CN, O 2  CR 4 , NHCOR 4 , NHCO 2  R 4 , NHSO 2  R 4 , CO 2  R 4 , CON(R 4 ) 2 , COR 4 , C 1  -C 8  straight or branched chain alkyl or C 3  -C 8  cycloalkyl, optionally substituted with one or more of (a)-(m), or Phenyl, optionally substituted with one or more of the preceeding groups listed under (a)-(n); and R 4  is H, C 1  -C 6  straight or branched chain alkyl or C 3  -C 8  cycloalkyl optionally substituted with one or more of fluorine, chlorine, hydroxy, C 1  -C 4  alkoxy, C 1  -C 4  acyl, C 1  -C 4  acyloxy, or O 2  CCH 2  N(CH 3 ) 2 , or Phenyl, optionally substituted with one or more of fluorine, chlorine, C 1  -C 4  straight or branched chain alkyl, hydroxy, C 1  -C 4  alkoxy, C 1  -C 4  acyl, C 1  -C 4  acyloxy, or O 2  CCH 2  N(CH 3 ) 2 .

CROSS-REFERENCE TO RELATED APPLICATION

This application is the 371 (National Phase) patent application of PCTapplication PCT/US96/00718, filed Jan. 29, 1996, which was acontinuation-in-part application of U.S. patent application Ser. No.08/384,278, filed Feb. 3, 1995, now abandoned.

BACKGROUND OF THE INVENTION

The subject invention discloses new and useful phenyloxazolidinonecompounds having a nitrogen containing hetero-aromatic ring substitutionattached through one of the nitrogen atoms. More particularly a 5-membernitrogen containing aromatic ring having from 1 to 4 nitrogen atoms oneof which binds to the phenyloxazolidinone. The compounds are usefulantimicrobial agents, effective against a number of human and veterinarypathogens, including gram-positive aerobic bacteria such asmultiply-resistant staphylococci, streptococci and enterococci as wellas anaerobic organisms such as Bacteroides spp. and Clostridia spp.species, and acid-fast organisms such as Mycobacterium tuberculosis,Mycobacterium avium and Mycobacterium spp.

INFORMATION DISCLOSURE

The present compounds are related by their phenyloxazolidinone ringstructure to the compounds disclosed in the publications below exceptthat the subject compounds have a nitrogen containing hetero-aromaticring substitution attached to the phenyloxazolidinone by one of thenitrogen atoms. This attachment point facilitates a different but easiersynthesis than a corresponding carbon--carbon bond structure andtherefore presents an advantage over such compounds. The instantcompounds are unique and have useful antibacterial activity.

WO93/23384 application discloses oxazolidinones containing a substituteddiazine moiety and their uses as antimicrobials.

WO93/09103 application discloses substituted aryl andheteroaryl-phenyl-oxazolidinones useful as antibacterial agents. In oneaspect, it discloses 5-member nitrogen hetero-aromatic rings attached toa phenyloxazolidinone although there is no synthesis disclosed whichwould permit attachment through the nitrogen atom (see, Chart C (y, w,ee and ff)).

WO90/02744 application discloses5'indolinyl-5β-amidomethyloxazolidinones, 3-(fused-ringsubstituted)phenyl-5β-amidomethyloxazolidinones, and 3-(nitrogensubstituted)phenyl-5β-amidomethyloxazolidinones which are useful asantibacterial agents.

Other references disclosing various oxazolidinones include U.S. Pat.Nos. 4,801,600, 4,921,869, Gregory W. A., et al., J. Med. Chem., 32,1673-81 (1989); Gregory W. A., et al., J. Med. Chem., 33, 2569-78(1990); Wang C., et al., Tetrahedron, 45, 1323-26 (1989); and Brittelli,et al., J. Med. Chem., 35, 1156 (1992).

European Patent Publication 352,781 discloses phenyl and pyridylsubstituted phenyl oxazolidinones.

European Patent Publication 316,594 discloses 3-substituted styryloxazolidinones.

European Patent Publication 312,000 discloses phenylmethyl andpyridinylmethyl substituted phenyl oxazolidinones.

U.S. Pat. No. 5,254,577 discloses nitrogen hetero-aromatic ringsattached to phenyloxazolidinone but not by the hetero-aromatic nitrogen(see, Col. 19 and 43).

SUMMARY OF THE INVENTION

In one aspect the subject invention is a compound of structural FormulaI: ##STR2## or pharmaceutically acceptable salts thereof wherein: Q is ahetero-aromatic 5-member ring bound to the aromatic ring of I at thenitrogen of the structures i, ii, iii, iv, v, vi, vii, viii, or ix:##STR3## or alternatively Q can be a benzoannulated hetero-aromatic5-member ring bound to the aromatic ring of I at the nitrogen of thestructures x, xi, xii, xiii, xiv, xv, xvi or xviii: ##STR4## R¹ isindependently H, OCH₃, F, or Cl; R² is

(a) hydrogen,

(b) C₁ -C₈ alkyl optionally substituted with one or more of thefollowing: F, Cl, hydroxy, C₁ -C₈ alkoxy, C₁ -C₈ acyloxy;

(c) C₃ -C₆ cycloalkyl;

(d) amino;

(e) C₁ -C₈ alkylamino;

(f) C₁ -C₈ dialkylamino;

(g) C₁ -C₈ alkoxy;

R³ is each independently selected from

(a) H,

(b) F, Cl, Br,

(c) OR⁴,

(d) SR⁴,

(e) S(O)_(n) R⁴ (n is 1 or 2),

(f) CN,

(g) O₂ CR⁴,

(h) NHCOR⁴,

(i) NHCO₂ R⁴,

(j) NHSO₂ R⁴,

(k) CO₂ R⁴,

(l) CON(R⁴)₂,

(m) COR⁴,

(n) C₁ -C₈ straight or branched chain alkyl or C₃ -C₈ cycloalkyl,optionally substituted with one or more of (a)-(m), or

(o) Phenyl, optionally substituted with one or more of the preceedinggroups listed under (a)-(n); and

R⁴ is

(a) H,

(b) C₁ -C₆ straight or branched chain alkyl or C₃ -C₈ cycloalkyl,optionally substituted with one or more of fluorine, chlorine, hydroxy,C₁ -C₄ alkoxy, C₁ -C₄ acyl, C₁ -C₄ acyloxy, or O₂ CCH₂ N(CH₃)₂, or

(c) Phenyl, optionally substituted with one or more of fluorine,chlorine, C₁ -C₄ straight or branched chain alkyl, hydroxy, C₁ -C₄alkoxy, C₁ -C₄ acyl, C₁ -C₄ acyloxy, or O₂ CCH₂ N(CH₃)₂.

DETAILED DESCRIPTION OF THE INVENTION

The present invention discloses novel substituted 5-member nitrogenheterocyclic phenyloxazolidinones according to structural Formula Iabove.

"Alkyl" means carbon atom chains having the designated number of carbonatoms which can be either straight chained or branched.

"Alkoxy" means the designated number of carbon atoms attached to anoxygen forming such groups as methoxy (--OCH₃), ethyloxy, butyloxy, etc.and isomeric forms thereof.

"Acyloxy" means the designated number of carbon atoms to form an organicacid where the OH group has been deleted, such as acetyl, CH₃ CO--;benzoyl, C₆ H₅ CO--.

"Cycloalkyl" means the designated number of carbon atoms formingcyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc. and isomericforms thereof.

"Amino" means an NH₂, "alkylamino" is where one of the hydrogenpositions is replaced by an alkyl and "dialkylamino" is where bothhydrogens are replaced by an alkyl group.

"Pharmaceutically acceptable salts" are acid addition salts which can beprepared by any of the art recognized means. Typical, acid additionsalts include hydrochloride, hydrobromide, hydroiodide, sulfate,phosphate, acetate, propionate, lactate, malate, succinate, tartrate,cyclohexanesulfamates, methanesulfonates, ethanesulfonates,benxenesulfonates, toluenesulfonates, fumarates and otherpharmaceutically acceptable couter ions for amines.

The compounds are useful as antimicrobial agents, effective against anumber of human and veterinary pathogens, particularly aerobicGram-positive bacteria, including multiply-antibiotic resistantstaphylococci and streptococci, as well as anaerobic organisms such asbacteroides and clostridia species, and acid-fast organisms such asMycobacterium tuberculosis and other mycobacterium species.

The pharmaceutical compositions of this invention may be prepared bycombining the compounds of Formula I of this invention with a solid orliquid pharmaceutically acceptable carrier and, optionally, withpharmaceutically acceptable adjuvants and excipients employing standardand conventional techniques. Solid form compositions include powders,tablets, dispersible granules, capsules, cachets and suppositories. Asolid carrier can be at least one substance which may also function as adiluent, flavoring agent, solubilizer, lubricant, suspending agent,binder, tablet disintegrating agent, and encapsulating agent. Inertsolid carriers include magnesium carbonate, magnesium stearate, talc,sugar, lactose, pectin, dextrin, starch, gelatin, cellulosic materials,low melting wax, cocoa butter, and the like. Liquid form compositionsinclude solutions, suspensions and emulsions. For example, there may beprovided solutions of the compounds of this invention dissolved in waterand water-propylene glycol and water-polyethylene glycol systems,optionally containing suitable conventional coloring agents, flavoringagents, stabilizers and thickening agents.

Preferably, the pharmaceutical composition is provided employingconventional techniques in unit dosage form containing effective orappropriate amounts of the active component, that is, the compound ofFormula I according to this invention.

The quantity of active component, that is the compound of Formula Iaccording to this invention, in the pharmaceutical composition and unitdosage form thereof may be varied or adjusted widely depending upon theparticular application, the potency of the particular compound, thedesired concentration. Generally, the quantity of active component willrange between 0.5% to 90% by weight of the composition.

In therapeutic use for treating, or combatting, bacterial infections inwarm-blooded animals, patients suffering from an antimicrobialinfection, the compounds or pharmaceutical compositions thereof will beadministered orally and/or parenterally at a dosage to obtain andmaintain a concentration, that is, an amount, or blood-level of activecomponent in the animal undergoing treatment which will beantibacterially effective. Generally, such antibacterially effectiveamount of dosage of active component will be in the range of about 0.1to about 100, more preferably about 3.0 to about 50 mg/kg of bodyweight/day. It is to be understood that the dosages may vary dependingupon the requirements of the patient, the severity of the bacterialinfection being treated, and the particular compound being used. Also,it is to be understood that the initial dosage administered may beincreased beyond the above upper level in order to rapidly achieve thedesired blood-level or the initial dosage may be smaller than theoptimum and the daily dosage may be progressively increased during thecourse of treatment depending on the particular situation. If desired,the daily dose may also be divided into multiple doses foradministration, e.g., two to four times per day.

The compounds of Formula I according to this invention are administeredparenterally, i.e., by injection, for example, by intravenous injectionor by other parenteral routes of administration. Pharmaceuticalcompositions for parenteral administration will generally contain apharmaceutically acceptable amount of the compound according to FormulaI as a soluble salt (acid addition salt or base salt) dissolved in apharmaceutically acceptable liquid carrier such as, for example,water-for-injection and a buffer to provide a suitably buffered isotonicsolution, for example, having a pH of about 3.5-6. Suitable bufferingagents include, for example, trisodium orthophosphate, sodiumbicarbonate, sodium citrate, N-methylglucamine, L(+)-lysine andL(+)-arginine to name but a few representative buffering agents. Thecompound according to Formula I generally will be dissolved in thecarrier in an amount sufficient to provide a pharmaceutically acceptableinjectable concentration in the range of about 1 mg/ml to about 400mg/ml of solution. The resulting liquid pharmaceutical composition willbe administered so as to obtain the above-mentioned antibacteriallyeffective amount of dosage. The compounds of Formula I according to thisinvention are advantageously administered orally in solid and liquiddosage forms.

The most preferred compounds in this series would be prepared as theoptically pure enantiomers having the (S)- configuration according tothe Cahn-Ingold-Prelog notation at C5 of the oxazolidinone ring.Optically pure material could be prepared by one of a number ofasymmetric syntheses or by resolution from a racemic modification byselective crystallization of a salt from, for example, the racemicmodification of intermediate amine 10 (as described in Chart II) with anappropriate optically active acid such as dibenzoyl tartarate or10-camphorsulfonic acid, followed by treatment with base to afford theoptically active amine. Although the (S)- enantiomer of this series ofcompounds is preferred since it is pharmacologically active as anantibacterial agent, the racemic modification is also useful in the samemanner as the pure (S)- enantiomer: the difference being that twice asmuch racemic material is required to elicit the same antibacterialeffect. In addition, it will be apparent to those skilled in the artthat when a chiral center exists in any of the substituents bonded to Qthat diastereomers are possible. These diastereomers, either in theracemic or configurationally enriched forms, are within the scope ofcompounds of structural Formula I of this invention.

The preferred method of preparation of compounds of structural Formula Iin highly enantiomerically enriched form is depicted in Charts I--VIII.

As shown in Chart I, 5-ring heterocyclics of general structure 1 (wheren=number of nitrogen atoms in the ring), available either commerciallyor by syntheses described in the literature (see for example, Katritzky,et al. in "Comprehensive Heterocyclic Chemistry") are treated with asubstituted nitrobenzene derivative 2 (Y is halogen ortrifluoromethanesulfonyloxy) in a suitable base and solvent combination,for example potassium carbonate in DMSO, at a suitable temperature,typically ambient to 90° C., to afford adduct 3. This method works wellfor 5-ring heterocyclics such as imidazole, pyrazole, and the like. For5-ring heterocyclics 1, such as pyrrole or indole and the like, theheterocyclic is added to a suspension of a strong base such as sodiumhydride, potassium tert-butoxide, or the like in THF or DME or similarsolvents to form the alkalai metal salt 4, which is then treated withnitroaromatic 2 at temperatures in the range of 0° C. to the refluxtemperature of the solvent to afford adduct 3. The nitro derivative 3 isthen reduced by catalytic hydrogenation in the presence of a suitablecatalyst, such as palladium on carbon, W-2 Raney nickel or platinum onsulfide carbon, in a suitable solvent, such as ethyl acetate, THF,methanol or combinations therof, to afford the aniline derivative 5.When THF is used as solvent for this reduction, it is not necessary toremove the catalyst by filtration or to isolate aniline derivative 5,but merely to purge the reaction vessel with an inert gas such asnitrogen and add saturated sodium bicarbonate solution and treat theresulting cooled reaction mixture with either benzyl or methylchloroformate to give the corresponding benzyl (R is CH₂ Ph) or methylcarbamate (R is CH₃) derivatives 6.

Either of the carbamate derivatives 6 can be deprotonated with a lithiumbase such as n-butyllithium, lithium diisopropylamide (LDA), or lithiumbis(trimethylsilyl)amide (LHMDS) in a suitable solvent such as THF,N,N-dimethylformamide (DMF), or mixtures thereof, at a suitabletemperature, typically -78° C. to -40° C. to give a lithiatedintermediate which is directly treated with (R)-(-)-glycidyl butyrate.Warming this reaction mixture to ambient or higher temperatures thenaffords the (hydroxymethyl)oxazolidinone 7 in highly enantiomericallyenriched form.

Chart II describes the conversion of (hydroxymethyl)oxazoldinone 7 intooxazoldinone antibacterial agents of Structural Formula I. As shown,compound 7 can be converted into the corresponding mesylate (R=CH₃) ortosylate (R=p-CH₃ C₆ H₄) by treatment with methanesulfonyl chloride inthe presence of triethylamine or pyridine or p-toluenesulfonyl chloridein the presence of pyridine, respectively. The resulting sulfonate 8 canbe treated with an alkalai metal azide, such as sodium or potassiumazide in an aprotic dipolar solvent such as DMF or N-methylpyrrolidinone(NMP) with an optional catalyst such as 18-crown-6 at a temperature inthe range of 50-90° C. to afford azide 9. The azide 9 can be reduced tothe corresponding amine 10 by hydrogenation in the presence of apalladium, platinum or nickel catalyst, in an appropriate solvent suchas ethyl acetate, THF, or methanol. Alternatively, azide 9 can bereduced to amine 10 by treatment with triphenylphosphine or othertrivalent phosphorus compounds in a solvent such as THF, followed byaddition of water. Amine 10 can also be prepared by treatment of thesulfonate 8 with potassium phthalimidate in DMF at 40-60° C. or inrefluxing acetonitrile to afford the phthalimide 11, which isdeprotected by treatment, for example, with aqueous methylamine inrefluxing ethanol. A more direct route to amine 10 is to treat sulfonate8 with aqueous ammonia solution in an isopropyl alcohol-THF solventsystem in a sealed tube heated at 75-105° C. in an oil bath. Amine 10 isthen acylated by reactions well-known to those skilled in the art togive (acylaminomethyl)oxazoldinones of structural formula 12. Forexample, amine 10 can be treated with an acid chloride or anhydride inthe presence of a base such as pyridine or triethylamine at temperaturesranging from -40-40° C. to provide the acyl derivative 12. It can alsobe seen that other acyl derivatives, such as carbamates, can be preparedunder similar reaction conditions. It can easily be seen thatpreparation of 12 provides an example of compounds of Structural FormulaI. It can also be seen that in some cases, 12 can be transformed intoother compounds of Structural Formula I by treatment with 40% aqueousformaldehyde in dimethyl sulfoxide at temperatures in the range of90-150° C. optionally in the presence of an acid catalyst to afford thecorresponding hydroxymethyl derivative 13.

Alternatively, compound 13 can be prepared by a less direct route, whichoffers the potential of providing other regioisomers that cannot bereadily obtained by hydroxymethylation. As shown in Chart III,alkoxycarbonyl derivatives of 5-membered ring heterocycles, 14 (wherem=number of methylenes), either available commercially or prepared byliterature methods, can be treated with a nitrobenzene derivative 2 in asuitable solvent, such as DMSO, DMF, or the like, in the presence of asuitable base such as potassium carbonate at a suitable temperature inthe range ambient to 90° C. to afford the biaryl derivative 15. Theresulting nitro derivative is then reduced by catalytic hydrogenation inthe presence of a suitable catalyst, such as palladium on carbon, W-2Raney nickel, or platinum on sulfide carbon, in a suitable solvent, suchas ethyl acetate, THF, methanol, or combinations thereof, to affordaniline derivative 16. When THF is used as solvent for this reduction,it is not necessary to remove the catalyst by filtration or to isolateaniline derivative 16, but merely to purge the reaction vessel with aninert gas such as nitrogen and add saturated sodium bicarbonate solutionand treat the corresponding mixture with with either benzyl or methylchloroformate for give the corresponding benzyl (R=CH₂ Ph) or methyl(R=CH₃) carbamate derivatives 17. The ester group of either of thecarbamate derivatives 17 can be reduced with either lithium borohydrideor possibly with borane-THF complex to afford the corresponding alcohol18. It can be seen by those skilled in the art that subsequenttransformations of 18 will necessitate the protection of the hydroxylgroup. This can be accomplished, for example, by preparation of thetert-butyldimethyl silyl (TBS) ether 19 (R=Si(CH₃)₂ t-Bu) by treatmentof 18 with tert-butyldimethylchlorosilane in the presence of a base suchas imidazole or diisopropylethylamine, optionally in the presence of4-dimethylaminopyridine as a catalyst, in a suitable solvent such asDMF, THF, or dichloromethane. Either of the carbamate derivatives 19 canbe deprotonated with a lithium base such as lithium diisopropylamide(LDA) or lithium bis(trimethylsilyl)amide (LHMDS), in a suitable solventsuch as THF, DMF or mixtures therof, at a suitable temperature,typically -78° C. to -40° C. to give a lithiated intermediate which isdirectly treated with (R)-(-)-glycidiyl butyrate. Warming this reactionmixture to ambient or higher temperatures then affords the(hydroxymethyl)oxazoldinone 20 in highly enantiomerically enriched form.

Chart IV describes the conversion of (hydroxymethyl)oxazolidinone 20into oxazolidinone antibacterial agents of Structural Formula I. Asshown, compound 20 can be converted to the corresponding(acylaminomethyl)oxazoldinone 21 (R=straight or branched chain alkyl) bya sequence of reactions identical with that used to convert 7 to 12 inChart II. (Acylaminomethyl)oxazolidinone 21 can then be deprotected by anumber of methods, notably by treatment with methanolic HCl solution atreflux or by treatment with mixtures of acetic acid in THF-water attemperatures of 40-90° C. to afford alcohol 22. Alcohol 22 is an exampleof an oxazolidinone antibacterial agent of Structural Formula I. Furthertransformations outlined in Chart IV can be used to prepare othercompounds of Structural Formula I from compound 22. As shown, alcohol 22can be oxidized by treatment with reagents such as pyridinium dichromatein DMF or by treatment with oxgen gas in the presence of a noble metalcatalyst in water solution or other methods known to thoses skilled inthe art, to afford carboxylic acid 23. Carboxylic acid 23 can beesterified by treatment with an appropriate alkyl halide in the presenceof a base such as potassium carbonate in an appropriate solvent, such asacetone, to give ester 24 (R=straight or branched chain alkyl).Alternatively, ester 24 can be obtained by addition of carboxylic acid23 to a solution of gaseous HCl dissolved in an appropriate alcohol, orby other means known to those skilled in the art.

Chart V outlines methods by which alcohol 22 can be converted into othercompounds of Structural Formula I. As shown, 22 can be converted intothe corresponding mesylate (R=CH₃) or tosylate (R=p-CH₃ C₆ H₄) bytreatment with methanesulfonyl chloride in the presence of triethylamineor pyridine or with p-toluenesulfonyl chloride in the presence ofpyridine. The resulting sulfonate derivative 25 can be treated with analkalai metal salt of a mercaptan (R=straight or branched chain alkyl oraryl) in an aprotic dipolar solvent such as DMF, DMSO, or acetonitrilewith an optional catalyst such as 18-crown-6 at a temperature in therange of ambient to 90° C. to afford sulfide 26. Sulfide 26 can then befurther transformed into either sulfoxide 27 or sulfone 28 by oxidationwith appropriate stoichiometric amounts of a suitable oxidizing agent,such as m-chloroperoxybenzoic acid (MCPBA) in a suitable solvent such asdichloromethane, diethyl ether, or the like. Alternatively, sulfone 28could be obtained directly by treatment with osmium tetroxide orruthenium tetroxide in the presence of sodium periodate or by treatmentwith potassium hydrogen persulfate. Compounds 26, 27, and 28 constituteexamples of compounds of Structural Formula I.

Other possible transformations of alcohol 22 are shown in Chart V. Asshown, sulfonate derivative 25 can be treated with an alkalai metalazide in a dipolar aprotic solvent such as DMF, DMSO, acetonitrile orthe like, optionally in the presence of a catalyst such as 18-crown-6,at a temperature in the range of 50-90° C. to afford azide 29. The azide29 can then be reduced to the corresponding amine 30 by hydrogenation inthe presence of a platinum, palladium, or nickel catalyst, in anappropriate solvent such as ethyl acetate, THF or methanol.Alternatively, azide 29 can be reduced by treatment withtriphenylphoshine or other trivalent phosphorus compounds in a solventsuch as THF, followed by addition of water. Amine 30 can then be used toform the corresponding sufonamide derivative 31 by treatment with anappropriate sulfonyl chloride (R=straight or branched chain alkyl, oraryl) in an appropriate solvent, such as pyridine. It can be seen thatsulfonamide derivative 31 is an example of compounds of StructuralFormula I.

Due to the shortage of commercially available 3-substitutedheterocyclics in the pyrrole, pyrazole, or triazole series, some of thepossible compounds of Structural formula I cannot be readily prepared byroutes described in the previous Charts. As a result, the synthesis ofthese other heterocyclic oxazolidinone derivatives from anilinederivative 37 are described in Charts VI, VII, VIII, and IX.

The preparation of aniline derivative 37 is described in Chart VI. Asshown, nitroaromatic 2 is treated with benzylamine in the presence of asuitable base, such as triethylamine or N,N-diisopropylethylamine, in asolvent such as acetonitrile, to afford displacement product 32. Nitrocompound 32 can then be transformed into optically active oxazoldinonederivative 36 by methods used in Charts I and II to convert nitroderivative 3 into oxazolidinone 12. At this point in the synthesis,hydrogenolysis of 36 using palladium on carbon as catalyst and methanolas solvent serves to both remove the CbZ protecting group and the benzylprotecting group to give aniline 37.

Preparation of 3-substituted pyrrole derivatives can be accomplished asshown in Chart VI. Treatment of aniline 37 with the commerciallyavailable 3,5-dimethoxy-3-tetrahydrofurancarboxaldehyde under conditionsof acid catalysis, such as in refluxing acetic acid, to afford3-pyrrolecarboxaldehyde 38. Aldehyde 38 can then be transformed intoother pyrrole analogs, such as hydroxymethyl pyrrole 39, ester 40, oroxime derivative 41 by methods well-known to those skilled in the art.It can be seen that pyrroles 30, 40 and 41 constitute examples ofcompounds of structural Formula I.

Transformation of aniline 37 into substituted triazole derivatives isdescribed in Chart VII. As shown, diazotization of aniline 37 bytreatment with nitrous acid, followed by addition of sodium azide,allows formation of azide 42 which is a useful precursor to formation oftriazoles by means of a 1,3-dipolar cycloaddition with a substitutedacetylene, 43. As shown, treatment of azide 42 with a substitutedacetylene derivative 43 in a solvent such as benzene, toluene, and thelike, at temperatures in the range of ambient to 120° C., optionally inthe presence of a Lewis acid catalyst such as aluminum chloride, borontrifluoride etherate, titanium tetrachloride, or the like, affords thesubstituted triazole derivative 44. Alternatively, in the case where oneof the R³ groups of 43 is an acyl group, such as R⁴ CO in acetylene 45,the cycloaddition under the aforementioned conditions will givepreferentially the 4-acyl triazole derivative 46 with lesser amounts ofthe corresponding 5-acyl triazole derivative 47. Alternatively,functionality permissible in R³ of 44 can be used to transform 44 intoacyl derivatives 46 and/or 47. 4-Acyl triazole oxazolidinone 46 can betransformed into oxime derivatives 48 or hydroxy compound 49 by methodsknown to those skilled in the art. It can be seen that 46, 48 and 49constitute examples of compounds of structural Formula I.

Transformation of aniline 37 into both possible regioisomers ofsubstituted pyrazole derivatives is shown in chart VIII. As shown,diazotization of aniline 37 followed by reduction of the diazonium saltwith either tin II! chloride or in-situ generated sodium sulfite givesthe hyrazine derivative 50. It can be seen that hydrazine 50 can bereacted with triformylmethane, 51 (Synthesis 1989, 858), to form thepyrazole-4-carboxaldehyde 52, as shown. Alternatively, treatment ofhydrazine 50 with 4-methoxy-2-oxo-but-3-enoic acid, ethyl ester, 53(Helv. Chim. Acta 1967, 50, 128), will lead to the formation of theregioisomeric 3-carboethoxypyrazole 54. It can be seen that aldehyde 52and ester 54 can be converted into other series of analogs bytransformations described in Charts IV, V, and VI. It can be seen that52 and 54 constitute examples of compounds of structural Formula I.

Examples of heteroaryl-phenyloxazolidinones which can be prepared aspart of this invention are as follows:

(S)-N- 3-3-Fluoro-4-(1H-pyrrol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3-3-Fluoro-4-(3-carbomethoxy-1H-pyrrol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3-3-Fluoro-4-(1H-pyrrol-1-yl-3-carboxaldehyde)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3-3-Fluoro-4-(3-(hydroxyiminomethyl)-1H-pyrrol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3-3-Fluoro-4-(3-methoxyiminomethyl)-1H-pyrrol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3-3-Fluoro-4-(3-hydroxymethyl-1H-pyrrol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3- 3-Fluoro-4-3-(2-carboethoxyvinyl)-1H-pyrrol-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3- 3-Fluoro-4-3-(2-carboethoxyethyl)-1H-pyrrol-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3- 3-Fluoro-4-3-(3-hydroxypropyl)-1H-pyrrol-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3- 3-Fluoro-4-3-(3-methanesulfonylaminopropyl)-1H-pyrrol-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3-3-Fluoro-4-(1H-imidazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3-3-Fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3-3-Fluoro-4-(4-ethyl-1H-imidazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3- 3-Fluoro-4-4-(carbomethoxy)-1H-imidazol-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3- 3-Fluoro-4-4-(hydroxymethyl)-1H-imidazol-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3- 3-Fluoro-4-4-(2-hydroxyethyl)-1H-imidazol-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3- 3-Fluoro-4-1H-imidazol-1-yl-4-carboxaldehyde!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3- 3-Fluoro-4-3-(hydroxyiminomethyl)-1H-imidazol-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3- 3-Fluoro-4-3-(methoxyiminomethyl)-1H-imidazol-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3-3-Fluoro-4-(1H-pyazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3-3-Fluoro-4-(4-methyl-1H-pyrazole-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3- 3-Fluoro-4-3-(hydroxymethyl)-1H-pyrazole-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3- 3-Fluoro-4-3-(carbomethoxy)-1H-pyrazole-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3-3-Fluoro-4-(1H-pyrazole-1-yl-3-carboxaldehyde)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3-3-Fluoro-4-(3-(hydroxyiminomethyl)-1H-pyrazole-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3-3-Fluoro-4-(3-(methoxyiminomethyl)-1H-pyrazole-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3- 3-Fluoro-4-4-(hydroxymethyl)-1H-pyrazole-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3- 3-Fluoro-4-4-(carbomethoxy)-1H-pyrazole-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3-3-Fluoro-4-(1H-pyrazole-1-yl-4-carboxaldehyde)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3-3-Fluoro-4-(4-(hydroxyiminomethyl)-1H-pyrazole-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3-3-Fluoro-4-(4-(methoxyiminomethyl)-1H-pyrazole-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3-3-Fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3- 3-Fluoro-4-3-mercapto-4H-1,2,4-triazol-4-yl!phenyl!-2-oxo-5-oxazolidinyl!methylacetamide;

(S)-N- 3- 3-Fluoro-4-3-methylthio-4H-1,2,4-triazol-4-yl!phenyl!-2-oxo-5-oxazolidinyl!methylacetamide;

(S)-N- 3- 3-Fluoro-4-4H-1,2,4-triazol-4-yl!phenyl!-2-oxo-5-oxazolidinyl!methylacetamide;

(S)-N- 3-3-Fluoro-4-(1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3-3-Fluoro-4-(4-carbomethoxy-1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3-3-Fluoro-4-(4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3-3-Fluoro-4-(4-(1-hydroxyethyl)-1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3-3-Fluoro4-(1H-1,2,3-triazol-1-yl-4-carboxaldehyde)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3-3-Fluoro-4-(4-(hydroxyiminomethyl)-1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide,oxime;

(S)-N- 3-3-Fluoro-4-(4-(methoxyiminomethyl)-1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3-3-Fluoro-4-(4-acetyl-1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3-3-Fluoro-4-(4-(1-hydroxyiminoethyl)-1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3-3-Fluoro-4-(4-(1-methoxyiminoethyl)-1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3-3-Fluoro-4-(2H-1,2,3-triazol-2-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3-3-Fluoro-4-(1H-1,2,3,4-tetrazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3-3-Fluoro-4-(2H-1,2,3,4-tetrazol-2-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3-3-Fluoro-4-(1H-indol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3-3-Fluoro-4-(7-aza-1H-indol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3-3-Fluoro-4-(1H-benzimidazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3-3-Fluoro-4-(1H-indazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;

(S)-N- 3-3-Fluoro-4-(1H-benzotriazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;and

(S)-N- 3- 3-Fluoro-4-(1H-1,2,3-triazolo4,5b!-pyridin-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide.

Antibacterial Activity

The oxazolidinone antibacterial agents of this invention have usefulactivity against a variety of organisms. The in vitro activity ofcompounds of this invention can be assessed by standard testingprocedures such as the determination of minimum inhibitory concentration(MIC) by agar dilution as desribed in "Methods for DilutionAntimicrobial Susceptibility Tests for Bacteria That Grow Aerobically"(MFT) published January 1983 by the National Committee for ClinicalLaboratory Standards, 771 East Lancaster Avenue, Villanova, Pa. 19084,USA. The activity of selected compounds of this invention againstStaphylococcus aureus and Streptococcus pneumoniae are shown in Table 1.

                  TABLE 1    ______________________________________    In vitro Activities: Minimum Inhibitory Concentrations (μg/mL)    Example No.             S. aureus, UC ®9213                            S. pneumoniae, UC ®9912    ______________________________________    1        <0.5           <0.5    2        2              1    3        2              <0.5    4        4              1    5        4              1    6        1              <0.5    7        1              <0.5    8        4              1    9        >32            8    10       8              1    11       >16            1    12       0.25           <0.06    13       1              0.25    14       2              0.25    15       1              0.25    16       1              <0.25    17       1              0.5    18       4              0.5    19       4              0.5    20       4              1    21       0.5            0.25    22       8              0.5    23       4              0.5    24       4              0.5    25       4              0.5    26       8              0.5    Vancomycin             1              0.5    ______________________________________

Antimicrobial activity was tested in vivo using the Murine Assayprocedure. Groups of female mice (six mice of 18-20 grams each) wereinjected intraperitoneally with bacteria which were thawed just prior touse and suspended in brain heart infusion with 4% brewers yeast UC9213(Staphylococcus aureus) or brain heart infusion (Streptococcus species).Antibiotic treatment at six dose levels per drug was administered onehour and five hours after infection by either oral intubation orsubcutaneous ("subcut.") routes. Survival was observed daily for sixdays. ED₅₀ values based on mortality ratios were calculated using probitanalysis. The subject compounds were compared against a well-knownantimicrobial (Vancomycin) as a control. The data are shown in Table 2.

                  TABLE 2    ______________________________________    In vivo Activities: ED.sub.50 (mg/Kg)    Example No.               S. aureus, UC ®9213                             Control, ED.sub.50    ______________________________________    3          9.5           vancomycin, 2.2    4          5.7           vancomycin, 2.4    6          4.7           vancomycin, 2.0    7          11.9          vancomycin, 1.2    15         7.3           --    16         5.5           --    ______________________________________

EXAMPLES Example 1

(S)-N- 3-3-Fluro-4-(1H-pyrrol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide

3-Fluoro-1-nitro-4-(1H-pyrrol-1-yl)benzene:

A slurry of 403 mg (630 mg of 60% in oil, 15.75 mmol) of sodium hydridein 85 mL THF was treated with 1.01 g (1.04 mL, 15 mmol) of pyrrole,followed by warming at 50° C. foe 15 min. The solution was then treatedwith 2.51 g (1.74 mL, 15.75 mmol) of 3,4-difluoronitrobenzene, followedby warming at reflux for 18 h. The mixture was then cooled and treatedwith 10 mL saturated ammonium chloride solution. The mixture was dilutedwith ethyl acetate and extracted with water (2×). Drying (Na₂ SO₄) andconcentration in vacuo afforded a dark brown solid, which waschromatographed over 75 g of 230-400 mesh silica gel, eluting with 30%(v/v) dichloromethane in hexane. These procedures afforded 2.05 g (66%)of the title pyrrole derivative as a light yellow solid. ¹ H NMR(CDCl₃): δ 8.14, 7.57, 7.16, 6.44.

3-Fluoro-1-(phenylmethoxycarbonylamino)-4-(1H-pyrrol-1-yl)benzene

A solution of 500 mg (2.43 mmol) of the previous pyrrole derivative in50 mL of 4:1 THF-water was treated with 75 mg of 5% platinum on sulfidecarbon followed by hydrogenation at one atmosphere for 18 h. The mixturewas then treated with 10 mL saturated NaHCO₃ solution and cooled to -20°C. The mixture was treated with 477 mg (0.42 mL, 2.79 mmol) of benzylchloroformate followed by warming to ambient temperature for 48 h. Themixture was filtered through celite, washing the filter cake withmethanol. The mixture was concentrated to ca. half the original volume,and the mixture was diluted with ethyl acetate and extracted with water(4×) and saturated NaCl solution. Drying (Na₂ SO₄) and concentration invacuo afforded a brown solid, which was chromatographed over 35 g230-400 mesh silica gel, eluting with 1:3:32methanol-dichloromethane-hexane, and then with 1:3:16methanol-dichloromethane-hexane. These procedures afforded 581 mg of thetitle CBZ derivative as a brown solid, suitable for use in the nextstep. ¹ H NMR (CDCl₃): 7.50, 7.40, 7.30, 7.09, 6.98, 6.35, 5.23.

(S)- 3- 3-Fluoro-4-(1H-pyrrol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methanol

A solution of 300 mg (0.97 mmol) of CBZ derivative 2 in 5 mL THF at -78°C. was treated with 1.06 mL (1.0M, 1.06 mmol) of lithiumbis(trimethylsilyl)amide followed by stirring at -78° C. for 30 min. Thesolution was treated with 153 mg (0.15 mmol) of (R)-(-)-glycidiylbutyrate followed by warming to 0° C. and then gradual warming toambient temperature for 48 h. The mixture was diluted with ethyl acetateand extracted with water and saturated NaCl solution. Drying (Na₂ SO₄)and concentration in vacuo afforded a red-brown oil which was subjectedto radial chromatography on a 2 mm chromatotron plate, eluting with 2%(v/v) methanol in dichloromethane and then with 5% (v/v) methanol indichloromethane. These procedures afforded 157 mg (59%) of the titleoxazoldinone as a light tan solid. High Resolution Mass Spectrum:Calculated For C₁₄ H₁₃ FN₂ O₃ : 276.0910. Found: 276.0918.

(S)- 3- 3-Fluoro-4-(1H-pyrrol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methylazide

A solution of 1.94 g (7.0 mmol) of the previous alcohol and 1.24 g (1.71mL, 12.25 mmol) of triethylamine in 60 mL dichloromethane at 0° C. wastreated with 1.0 g (0.68 mL, 8.78 mmol) of methanesulfonyl chloride,followed by stirring at 0° C. for 30 min. The solution was warmed toambient temperature and diluted with dichloromethane, followed byextraction with water (3×) and saturated NaCl solution. Drying (Na₂ SO₄)and concentration in vacuo afforded an amber oil which was dissolved in120 mL DMF, treated with 4.5 g (70 mmol) of sodium azide and warmed at60° C. for 18 h. The mixture was cooled and diluted with 75 mL of 1:1ether-ethyl acetate and extracted with water (6×40 mL). Drying (Na₂ SO₄)and concentration in vacuo afforded 2.13 g (100%) of the title azide asa yellow-brown solid, sufficiently pure for use in the next step. HighResolution Mass Spectrum: Calculated For C₁₄ H₁₂ FN₅ O₂ : 302.1053.Found: 302.1056.

(S)-N- 3-3-Fluro-4-(1H-pyrrol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide

A solution of 1.0 g (3.32 mmol) of the previous azide in 30 mL methanoland 15 mL THF was treated with 200 mg of platinum on sulfide carbonfollowed by hydrogenation at one atmosphere for 24 h. The solution wasfiltered though celite, washing the filter cake with THF. The filtratewas concentrated in vacuo and the residue was dissolved in pyridine andtreated with acetic anydride followed by stirring at ambient temperaturefor 48 h. The solution was concentrated under high vacuum, and the brownsolid obtatined was dissolved in ethyl acetate and extracted with water(2×). Drying (Na₂ SO₄) and concentration in vacuo afforded a brown solidwhich was chromatographed over 50 g of 230-400 mesh silica gel, elutingwith 1% (v/v) methanol in dichloromethane and then with 2% (v/v)methanol in dichloromethane. These procedures afforded 582 mg (56%) ofthe title compound as an off-white solid, mp 198-199.5° C. HighResolution Mass Spectrum: Calculated For CHFNO: 317.1176. Found:317.1182.

Example 2

(S)-N- 3-3-Fluoro-4-(1H-pyrazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide:

3-Fluoro-1-nitro-4-(1H-pyrazol-1-yl)benzene

A solution of 2.0 g (29.37 mmol) of pyrazole and 8.12 g (58.75 mmol) ofpotassium carbonate in 70 mL of DMSO was treated with 4.67 g (3.25 mL,29.37 mmol) of 3, 4-difluoronitrobenzene followed by warming at 90° C.for 18 h. The solution was cooled and diluted with 100 mL water and wasextracted with ethyl acetate (2×100 mL). The organic layers wereextracted with water (5×100 mL) and with saturated NaCl solution (75mL). Drying (Na₂ SO₄) and concentration in vacuo afforded an off-whitesolid which was recrystallized from hot hexanes to afford 5.3 g (87%) ofthe title pyrazole derivative as an off-white solid, mp 128-129° C.

3-Fluoro-1-(phenylmethoxycarbonylamino)-4-(1H-pyrazol-1-yl)benzene

A solution of the previously prepared pyrazole in 120 mL THF was treatedwith 1.5 g of W-2 Raney Nickel followed by hydrogenation under 40 psi ofhydrogen for 16 h. The solution was filtered through celite, washing thefilter cake with acetone, and concentration of the filtrate in vacuo.The yellow residue obtained was dissolved in 100 mL THF and treated with75 mL saturated NaHCO₃ solution, followed by cooling to 0° C. Thesolution was then treated with 7.30 g (42.72 mmol) of benzylchloroformate followed by stirring at 0° C. for 30 min and then bywarming to ambient temperature for 1 h. The mixture was diluted with 125mL ethyl acetate and 100 mL water. The layers were separated and theaqueous layer was extracted with 100 ml ethyl acetate. The combinedorganic layers were extracted with saturated NaHCO₃ solution (2×100 mL)and saturated NaCl solution. Drying (Na₂ SO₄) and concentration in vacuoafforded a light beige solid, which was recrystallized fromchloroform-hexane to afford 5.92 g (79%) of the title compound asglistening white plates, mp 82-83° C.

(S)- 3-3-fluoro-4-(1H-pyrazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methanol

A solution of 3.0 g (9.63 mmol) of the CBZ derivative 2 in 130 mL THF at-78° C. was treated with 10.6 mL (1.0M, 10.60 mmol) of lithiumbis(trimethylsilyl)amide in THF followed by stirring at -78° C. for 30min. The solution was then treated with 1.53 g (1.50 mL, 10.60 mmol) ofneat (R)-(-)-glycidiyl butyrate, followed by stirring at -78° C. for 30min and then warming to ambient temperature for 18 h. The mixture wastreated with 2 mL saturated ammonium chloride solution, followed bydilution with 400 mL ethyl acetate. The mixture was extracted with water(2×100 mL) and saturated NaCl solution (200 mL). Drying (Na₂ SO₄) andconcentration in vacuo afforded a yellow solid which was recrystallizedfrom hot methanol to afford 2.28 g (85%) of compound 3 as fine whiteneedles, mp 180-181° C.

(S)- 3- 3-Fluoro-4-(1H-pyrazol-1yl)phenyl!-2-oxo-5-oxazolidinyl!methylmethanesulfonate

A slurry of 403 mg (1.45 mmol) of the previously prepared compound and882 mg (1.22 mL, 8.71 mmol) of triethylamine in 15 mL dichloromethane at0° C. was treated with 500 mg (0.34 ml, 4.36 mmol) of methanesulfonylchloride dropwise. The solution was stirred at 0° C. for 30 min,followed by warming to ambient temperature. The mixture was diluted with20 mL dichloromethane and extracted with water (2×25 mL) and saturatedNaHCO₃ solution. Drying (Na₂ SO₄) and concentration in vacuo afforded520 mg (ca. 100%) of the title mesylate, sufficiently pure for furtheruse. ¹ H NMR (DMSO-d₆): δ 8.16, 7.80, 7.48, 6.55, 5.05, 4.53, 4.23,3.89, 3.25.

(S)- 3-3-Fluoro-4-(1H-pyrazol-1yl)phenyl!-2-oxo-5-oxazolidinyl!methylazide

A solution of 518 mg (1.45 mmol) of the previous mesylate in 15 mL N,N-dimethylformamide was treated with 1.89 g (29.07 mmol) of sodium azidefollowed by warming at 70° C. for 48 h. The mixture was diluted with 100mL ethyl acetate followed by extraction with water (6×75 mL) andsaturated NaCl solution (75 mL). Drying (Na₂ SO₄) and concentration invacuo afforded a beige solid which was chromatographed over 50 g of230-400 mesh silica gel, eluting with 3% (v/v) acetone indichloromethane and then with 3.5% (v/v) methanol in dichloromethane.These procedures afforded 355 mg (81%) of the title azide as a whitesolid. ¹ H NMR (CDCl₃): δ 7.99, 7.92, 7.76, 7.24, 6.49, 4.83, 4.12,3.99, 3.74, 3.62.

(S)-N- 3-3-Fluoro-4-(1H-pyrazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide

A solution of 355 mg of the previous azide in 30 mL ethyl acetate wastreated with 150 mg of palladium on calcium carbonate followed byhydrogenation at one atmosphere for 18 h. The solution was then treatedwith 15 mL pyridine and 10 mL acetic anhydride followed by stirring atambient temperature for 18 h. The mixture was diluted with 100 mL ethylacetate and filtered through celite, washing the filter cake with ethylacetate. The mixture was concentrated in vacuo, and the remainingpyridine and acetic anhydride removed by short path distillation underhigh vacuum (0.2 mmHg/hot water bath). The solid residue obtained wasrecrystallized from hot acetone-hexane to afford 192 mg (51%) of thetitle compound as a white solid, mp 183-184° C.

Example 3

(S)-N- 3-3-Fluoro-4-(1H-imidazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide

3-Fluoro-4-(1H-imidazol-1-yl)nitrobenzene

A solution of 2.14 g (31.4 mmol) of imidazole and 10.9 g (62.8 mmol) ofdibasic potassium phosphate in 190 mL DMSO was treated with 5.25 g (3.7mL, 32.9 mmol) of 3,4-difluoronitrobenzene followed by warming at 90° C.for 18 h. The solution was diluted with ethyl acetate and was extractedwith water. The water layer was back-extracted with ethyl acetate andthe combined organic layers were then extracted with water (2×). Theorganic layer was dried (Na₂ SO₄) and concentrated in vacuo to afford abrown solid. This material was chromatographed over 250 g of 230-400mesh silica gel, eluting with dichloromethane, and then with 1% (v/v)methanol in dichloromethane, and finally with 2% (v/v) methanol indichloromethane. These procedures afforded 6.0 g (92%) of the titlecompound as a bronze colored solid. ¹ H NMR (CDCl₃): δ 8.17, 7.96, 7.63,7.35, 7.26.

3-Fluoro-4-(1H-imidazol-1-yl)-1-(phenylmethoxycarbonylamino)benzene

A solution of 500 mg (2.41 mmol) of the previous nitro compound in 50 mLTHF was treated with 100 mg of 10% palladium on carbon, followed byhydrogenation at atmospheric pressure for 20 h. The mixture was treatedwith 60 mg of additional 10% palladium on carbon and hydrogenation atatmospheric pressure was continued for 5 h. The mixture was thenfiltered through celite washing the filter cake with methanol. Thefiltrate was concentrated in vacuo to afford a brown oil, which wasdissolved in 50 mL anhydrous THF, followed by treatment with 405 mg(4.82 mmol) of solid sodium bicarbonate. The solution was cooled to -20°C., followed by addition of 493 mg (0.43 mL, 2.89 mmol) of benzylchloroformate dropwise. The mixture was warmed to ambient temperaturefor 18 h, followed by dilution with ethyl acetate. The solution wasextracted with water (3×) and saturated sodium chloride solution. Drying(Na₂ SO₄) and concentration in vacuo afforded a light brown solid whichwas recrystallized from hot chloroform-hexane to afford 692 mg (92%) ofthe title compound as light brown crystals. High Resolution MassSpectrum: Calculated for C₁₇ H₁₄ FN₃ O₂ : 311.1070. Found: 311.1092.

(S)- 3-3-Fluoro-4-(1H-imidazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methanol

A solution of 500 mg (1.61 mmol) of the previous CBZ derivative in 22 mLTHF and 4 mL DMF at -78° C. was treated with 1.69 mL (1.69 mmol) oflithium bis(trimethylsilyl)amide followed by stirring at -78° C. for 20min. The solution was treated with 243 mg (0.24 mL, 1.69 mmol) of(R)-(-)-glycidyl butyrate followed by warming to 0° C. and then toambient temperature. After stirring 3 h at ambient temperature, TLCevidence suggested that no reaction had occurred. The solution was thenwarmed at 40° C. for 2 h, followed by cooling and stirring at ambienttemperature for 18 h. The solution was then diluted with ethyl acetateand extracted with water (3×). Drying (Na₂ SO₄) and concentration invacuo afforded a brown solid. This material was chromatographed over 40g of 230-400 mesh silica gel eluting with 2% (v/v) methanol indichloromethane and then with 5% (v/v) methanol in dichloromethane.These procedures afforded 214 mg (48%) of the title compound as a lightyellow solid. High Resolution Mass Spectrum: Calculated For C₁₃ H₁₂ FN₃O₃ : 277.0863. Found: 277.0876.

(S)- 3-3-Fluoro-4-(1H-imidazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methylazide

A solution of 150 mg (0.54 mmol) of the previous oxazolidinone and 96 mg(0.13 mL, 0.95 mmol) of triethylamine in 5 mL dichloromethane at 0° C.was treated with 77 mg (52 μL, 0.68 mmol) of methanesulfonyl chloride,followed by stirring at 0° C. for 30 min. The solution was warmed toambient temperature followed by dilution with dichloromethane andextraction with water (3×). Drying (Na₂ SO₄) and concentration in vacuoafforded a light brown foam. This material was dissolved in 10 mL DMFand treated with 525 mg (8.1 mmol) of sodium azide, followed by warmingat 60° C. for 48 h. The solution was cooled and diluted with ethylacetate followed by extraction with water (3×). Drying (Na₂ SO₄) andconcentration in vacuo afforded 163 mg (100%) of the title azide as ayellow oil. ¹ H NMR (CDCl₃): δ 8.15, 7.74, 7.46, 7.35, 7.29, 4.85, 4.12,3.90, 3.76, 3.59.

(S)-N- 3-3-Fluoro-4-(1H-imidazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide

A solution of 163 mg (0.54 mmol) of the azide in 8 mL pyridine wastreated with 85 mg of palladium on calcium carbonate and 110 mg (0.10mL, 1.08 mmol) of acetic anhydride. This mixture was hydogenated at oneatmosphere for 20 h. The mixture was then treated with 80 mg ofpalladium on calcium carbonate followed by hydrogenation at oneatmosphere for 4 h. The solution was filtered through celite, washingthe filter cake with ethyl acetate. The filtrate was concentrated underhigh vacuum, and the residue was subjected to radial chromatography on a2 mm chromatotron plate eluting with 2% (v/v) methanol indichloromethane and then with 5% (v/v) methanol in dichloromethane.These procedures afforded 84 mg (49%) of the title compound as a whitesolid. High Resolution Mass Spectrum: Calculated For C₁₅ H₁₅ FN₄ O₃ :318.1128. Found: 318.1140.

Example 4

(S)-N- 3-3-Fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide

3-Fluoro-1-nitro-4-(1H-1,2,4-triazol-1-yl)benzene

A solution of 5.0 g (72.4 mmol) of 1H-1,2,4-triazole and 25.22 g (144.8mmol) of dibasic potassium phosphate in 150 mL DMSO was treated with11.52 g (72.4 mmol) of 3,4-difluoronitrobenzene followed by warming at90° C. for 3 h. The solution was cooled and added to 500 mL water, andthe resulting white solid was collected by filtration and washed withwater. The white solid obtained was dried in vacuo (60° C./10 mmHg) toafford 10.79 g (72%) of the title compound as a white solid. HighResolution Mass Spectrum: Calculated for C₈ H₅ FN₄ O₂ : 208.0396. Found:208.0408.

3-Fluoro-4-(1H-1,2,4-triazol-1-yl)aniline

A solution of 8.7 g (41.83 mmol) of the previous nitro compound in 350mL of 1:1 methanol-THF was treated with 3.5 g of 10% palladium on carbonfollowed by hydrogenation under 45 psi of hydrogen pressure for 18 h.The solution was filtered through celite, washing the filter cake withmethanol. The filtrate was concentrated in vacuo and the residueobtained was chromatographed over 200 g of 230-400 mesh silica geleluting with 1% (v/v) methanol in dichloromethane and then with 3% (v/v)methanol in dichloromethane. These procedures afforded 4.0 g (54%) ofthe aniline derivative as an off-white solid. High Resolution MassSpectrum: Calculated for C₈ H₇ FN₄ : 178.0655. Found: 178.0673.

3-Fluoro-1-(phenylmethoxycarbonylamino)-4-(1H-1,2,4-triazol-1-yl)benzene

A solution of 4.0 g (22.5 mmol) of the previous aniline derivative in 50mL acetone was treated with 50 mL of saturated NaHCO₃ solution, followedby cooling to 0° C. The solution was treated with 8.0 g (6.78 mL, 47.26mmol) of benzyl chloroformate. The solution was warmed to ambienttemperature for 1 h, followed by addition to 300 mL water and extractionwith ethyl acetate (2×300 mL). The organic layer was extracted with 300mL water and dried (Na₂ SO₄). Concentration in vacuo afforded a beigesolid which was recrystallized from chloroform-hexane to afford 2.6 g(37%) of the title CBZ derivative. High Resolution Mass Spectrum:Calculated for C₁₆ H₁₃ FN₄ O₂ : 312.1022. Found: 312.1033.

(S)- 3-3-Fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methanol

A solution of 2.5 g (8.0 mmol) of the previously prepared CBZ derivativein 115 mL THF at -78° C. was treated with 8.8 mL (1.0M, 8.8 mmol) oflithium bis(trimethylsilyl)amide, followed by stirring at -78° C. for 30min. The solution was then treated with 1.27 g (1.25 mL, 8.8 mmol) of(R)-(-)-glycidiyl butyrate, followed by stirring at -78° C. for 15 min.The solution was then warmed to ambient temperature for 18 h. Themixture was treated with 2 mL saturated ammonium chloride solution,followed by dilution with 100 ml water and extraction with ethyl acetate(2×100 mL). Drying (Na₂ SO₄) and concentration in vacuo afforded asemi-solid, which was triturated with chloroform to provide 1.4 g (57%)of the title oxazolidinone. High Resolution Mass Spectrum: Calculatedfor C₁₂ H₁₁ FN₄ O₃ : 278.0815. Found: 278.0836.

(S)- 3-3-Fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methylazide

A slurry of 1.0 g (3.6 mmol) of the previously prepared oxazolidinoneand 548 mg (0.76 mL, 5.42 mmol) of triethylamine in 20 mLdichloromethane at 0° C. was treated with 495 mg (0.33 mL, 4.32 mmol) ofmethanesulfonyl chloride. The solution was then warmed to ambienttemperature for 2 h. The solution was then treated with 20 mL water andthe layers separated. The organic layer was dried (Na₂ SO₄) andconcentrated in vacuo to afford 1.0 g (75%) of the the intermediatemesylate as a tan solid. A soution of 1.34 g (3.6 mmol) of this materialand 2.34 g (36 mmol) of sodium azide in 36 mL of DMF was warmed at 70°C. for 18 h. The solution was cooled and diluted with 100 mL ethylacetate, followed by extraction with water (5×75 mL). Drying (Na₂ SO₄)and concentration in vacuo afforded 1 g (88%) of the title azide as anoff-white solid. ¹ H NMR Spectrum (CDCl₃): δ 8.65, 8.13, 7.91, 7.83,7.32, 4.85, 4.14, 3.92, 3.77, 3.63.

(S)-N- 3-3-Fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide

A solution of 100 mg (0.36 mmol) of the azide in 3 ml pyridine wastreated with 50 mg of palladium on calcium carbonate followed byhydrogenation at one atmosphere for 18 h. The solution was treated with0.2 mL acetic anhydride followed by stirring at ambeient temperature for18 h. The solvent was removed in vacuo and the residue dissolved inethyl acetate and extracted with water. The organic layer was dried (Na₂SO₄) and concentrated in vacuo to afford a light beige solid. Thismaterial was subjected to radial chromatography on a 2 mm plate elutingwith 2% (v/v) methanol in dichloromethane and then with 4% (v/v)methanol in dichloromethane. These procedures afforded 62 mg (54%) ofthe title compound as a white solid. High Resolution Mass Spectrum:Calculated for C₁₄ H₁₄ FN₅ O₃ : 319.1018. Found: 319.1087.

Example 5

(S)-N- 3-3-Fluoro-4-(1H-indol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide

3-Fluoro-4-(1H-indol-1-yl)nitrobenzene

A slurry of 334 mg (374 mg of 60% in oil, 9.35 mmol) of sodium hydridein 5 mL THF was treated with a solution of 1.0 g (8.5 mmol) of indole in5 mL THF, followed by stirring at ambient temperature for 15 min. Thesolution was then treated with 1.35 g (8.5 mmol) of3,4-difluoronitrobenzene. The solution was stirred at ambienttemperature for 48 h, followed by concentration in vacuo to afford brownoil which was dissolved in ethyl acetate and washed with water. Drying(Na₂ SO₄) and concentration in vacuo afforded an oil which waschromatographed over 100 g of 230-400 mesh silica gel, eluting with 20%(v/v) ethyl acetate in hexane. These procedures afforded 1.1 g (51%) ofthe title compound as a yellow solid. ¹ H NMR (CDCl₃): δ 8.23, 7.74,7.40, 7.35, 7.30, 6.80.

3-Fluoro-4-(1H-indole-1-yl)-1-(phenylmethoxycarbonylamino)benzene

A solution of 1.0 g (3.9 mmol) of the previously prepared nitro compoundin 5 mL THF was treated with 200 mg of W-2 Raney nickel followed byhydrogenation at one atmosphere for 18 h. The solution was filteredthrough celite, washing the filter cake with THF. The filtrate wasconcentrated in vacuo and the residue dissolved in 10 mL acetone andtreated with 8.2 mL saturated NaHCO₃ solution, followed by cooling to 0°C. and addition of 699 mg (4.1 mmol) of benzyl chloroformate. Thesolution was warmed to ambient temperature for 18 h, diluted with ethylacetate and extracted with water. Drying (Na₂ SO₄) and concentration invacuo afforded an oil, which was chromatographed over 75 g of 230-400mesh silica gel, eluting with 50% (v/v) ethyl acetate in hexane. Theseprocedures afforded 1.03 g (71%) of the title compound as a yellowsolid. ¹ H NMR (CDCl₃): δ 7.69, 7.60, 7.40, 7.25, 7.15, 6.70.

(S)- 3- 3-Fluoro-4-(1H-indol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methanol

A solution of 1.0 g (2.77 mmol) of the previous CBZ derivative in 5 mLTHF at -78° C. was treated with 3.05 mL (1.0M, 3.05 mmol) of lithiumbis(trimethylsilyl)amide in THF followed by stirring at -78° C. for 45min. The solution was treated with 440 mg (0.43 mL, 3.05 mmol) of(R)-(-)-glycidiyl butyrate followed by stirring at -78° C. for 15 min,warming to 0° C. for 15 min and finally warming to ambient temperaturefor 18 h. The mixture was diluted with ethyl acetate and extracted withwater. Drying (Na₂ SO₄) and concentration in vacuo afforded a semisolidwhich was chromatographed over 60 g of 230-400 mesh silica gel, elutingwith 2% (v/v) methanol in dichloromethane. These procedures afforded 630mg (70%) of the title compound as a white solid. ¹ H NMR (CDCl₃): δ7.69, 7.50, 7.38, 7.25, 6.71, 4.80, 4.09, 3.79.

(S)- 3-3-Fluoro-4-(1H-indol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methylazide

A solution of 484 mg (1.2 mmol) of the previous mesylate in 10 mL DMFwas treated with 390 mg (6 mmol) of sodium azide followed by warming at90° C. for 18 h. The solution was cooled and diluted with ethyl acetateand extracted with water. Drying (Na₂ SO₄) and concentration in vacuoafforded 336 mg (80%) of the title azide as a gum, sufficiently pure forfurther use. ¹ H NMR (CDCl₃): δ 7.72, 7.68, 7.51, 7.37, 7.20, 6.71,4.85, 4.13, 3.91, 3.77, 3.62.

(S)-N- 3-3-Fluoro-4-(1H-indol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide

A solution of 336 mg (0.96 mmol) of the previous azide in 5 mL ethylacetate was treated with 150 mg of 10% palladium on carbon followed byhydrogenation at one atomosphere for 18 h. The solution was filteredthrough celite, washing the filter cake with ethyl acetate. The filtratewas concentrated in vacuo to afford a light brown oil which wasdissolved in 2 mL pyridine and treated with 0.2 mL acetic anhydride,followed by stirring at ambient temperature for 60 h. The solution wasconcentrated under high vacuum, and the residue was dissolved inchloroform and extracted with water. Drying (Na₂ SO₄) and concentrationin vacuo afforded a gum which was subjected to radial chromatography ona 4 mm chromatotron plate, eluting with 1.5% (v/v) methanol indichloromethane and then with 2.5% (v/v) methanol in dichloromethane.These procedures afforded 277 mg (81%) of the title compound as a whitesolid. ¹ H NMR (CDCl₃): δ 7.70, 7.51, 7.33, 7.20, 6.71, 6.11, 4.84,4.12, 3.87, 3.70, 2.06.

Example 6

(S)-N- 3-3-Fluoro-4-(1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide

3-Fluoro-1-nitro-4-(1H-1,2,3-triazol-1-yl)benzene

A slurry of dibasic potassium phosphate, 38.0 g (0.218 mol), and1H-1,2,3-triazole, 7.53 g (6.3 mL, 0.109 mol), in 325 mLdimethylsulfoxide was treated dropwise with 3,4-difluoronitrobenzene,17.3 g (12.1 mL, 0.109 mol), with heating to 90° C. for 18 h. Themixture was cooled to room temperature, diluted with water (500 mL) andextracted with ethyl acetate (4×50 mL). Drying (Na₂ SO₄) andconcentrating in vacuo afforded a light yellow solid. This material waschromatographed over 600 g 230-400 mesh silica gel eluting withmethylene chloride, 1% (v:v), 2% (v:v) and 5% (v:v) methanol-methylenechloride to afford 11.38 g (50%) of3-Fluoro-1-nitro-4-(1H-1,2,3-triazol-1-yl)benzene as a light yellowsolid, mp=123-124.5° C., along with 9.66 g (43%) of regioisomer3-Fluoro-1-nitro-4-(2H-1,2,3-triazol-2-yl)benzene as a light yellowsolid, mp 137-139° C.

3-Fluoro-1-(phenylmethoxycarbonylamino)-4-(1H-1,2,3-triazol-1-yl)benzene

A solution of 5.0 g (24.0 mmol) of the previous compound in 400 mL of1:1 methanol-THF was treated with 3 g of W-2 Raney nickel. The mixturewas hydrogenated on a Parr shaker under 45 psi hydrogen pressure for 18h followed by filtering through celite, washing the filter cake withmethanol. Concentration in vacuo afforded a white solid which wasdissolved in 500 mL anhydrous THF, cooled to -20° C. and treated withsodium bicarbonate, 4.0 g (48.0 mmol) and benzyl chloroformate, 4.9 g(4.3 mL, 28.8 mmol). After stirring 72 h with gradual warming to roomtemperature, the solvent was removed under reduced pressure and theresulting oil was dissolved in 200 mL ethyl acetate. The mixture wasextracted with water (3×50 mL), dried (Na₂ SO₄) and concentrated invacuo to give a yellow solid. This material was cchromatographed over400 g 230-400 mesh silica gel eluting with methylene chloride, 1% (v:v)and 2% (v:v) methanol-methylene chloride to afford 6.18 g (82%) of thetitle compound as a white solid, mp 121-122° C.

(R)- 3-3-Fluoro-4-(1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methanol

A solution of 2.0 g (6.4 mmol) of the previous compound in 100 mLanhydrous THF at -78° C. was treated with 6.7 mL (1.0M, 6.7 mmol) oflithium bis(trimethylsilyl)amide in THF followed by stirring at -78° C.for 30 minutes. The mixture was treated with 960 mg (6.7 mmol) ofR-(-)-glycidyl butyrate, followed by warming to 0° C. with gradualwarming to room temperature. After 18 h, the mixture was quenched withsaturated aqueous ammonium chloride (30 mL) and extracted with ethylacetate (3×30 mL). Drying (Na₂ SO₄) and concentration in vacuo gave ayellow oily solid. The crude material was recrystallized from boiling2:1 methanol-ethyl acetate to afford 1.10 g (62%) of the title compoundas a white solid, mp 179-180.5° C.

(R)- 3-3-Fluoro-4-(1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methylazide

A slurry of 1.35 g (4.85 mmol) of the previous compound and 859 mg (1.18mL, 8.49 mmol) triethylamine in 60 mL dichloromethane at 0° C. wastreated with 695 mg (0.47 mL, 6.07 mmol) methanesulfonylchloridefollowed by warming to ambient temperature over 1 h. The mixture wasthen cooled to 0° C., treated with triethylamine, 859 mg (8.49 mmol),and methanesulfonyl chloride, 695 mg (6.07 mmol). After 5 minutes, themixture was extracted with water (3×20 mL), saturated aqueous sodiumbicarbonate (2×20 mL) and saturated aqueous sodium chloride (1×20 mL).Drying (Na₂ SO₄) and concentration in vacuo afforded 1.89 g of thecorresponding mesylate as a light yellow solid, which was dissolved in90 mL DMF and treated with 4.73 g (72.8 mmol) sodium azide and warmed at60° C for 18 h. The mixture was cooled to 0° C. and diluted with water(200 mL). The mixture was extracted with 1:1 ethyl ether-ethyl acetate(5×50 mL). The combined organic layers were then extracted with water(4×50 mL), dried (Na₂ SO₄) and concentrated in vacuo to afford 1.48 g(ca. 100%) of the title azide as an off-white solid, sufficiently purefor further use. ¹ H NMR (CDCl₃) δ 8.09, 7.98, 7.87, 7.29, 4.86, 4.16,3.94, 3.70.

(S)-N- 3-3-Fluoro-4-(1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide

A solution of 300 mg (0.99 mmol) of the previous azide in 12 mL THF wastreated with 750 mg of W-2 Raney nickel. The mixture was hydrogenated atatmospheric pressure for 18 h. The mixture was treated with 783 mg (0.80mL, 9.9 mmol) pyridine, and 505 mg (0.47 mL, 4.9 mmol) acetic anhydridefollowed by stirring for 2 h. The mixture was filtered through celite,washing the filter cake with ethyl acetate. The filtrate was extractedwith water (3×30 mL) and saturated aqueous sodium chloride (1×20 mL).Drying (Na₂ SO₄) and concentration in vacuo gave an off-white solid. Thecrude material was recrystallized from boiling 10:1 ethyl acetate-hexaneto give 210 mg (66%) of the title compound as a white solid, mp 193-194°C.

Example 7

(S)-N- 3-3-Fluoro-4-(1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!-2,2-dichloroacetamide

A solution of 275 mg (0.91 mmol) of (R)- 3-3-Fluoro-4-(1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methylazide(from Example 6) in 15 mL THF was treated with 1.5 g of W-2 Raneynickel, and hydrogenated at atmospheric pressure. After 18 h, themixture was filtered through celite, washing the filter cake withmethanol. The filtrate was concentrated in vacuo and the resulting oilwas slurried in 15 mL methylene chloride, cooled to 0° C. and treatedwith 138 mg (0.19 mL, 1.36 mmol) triethylamine, and 161 mg (0.11 mL,1.09 mmol) dichloroacetyl chloride. After stirring at ambienttemperature for 24 h, the mixture was diluted with methylene chlorideand extracted with water (3×20 mL) and saturated aqueous sodium chloride(1×20 mL). Drying (Na₂ SO₄) and concentration in vacuo afforded anoff-white solid. The crude material was subjected to radialchromatography on a 4 mm chromatotron plate eluting with dichloromethaneand 2% (v/v) methanol-dichloromethane. These procedures afforded 182 mg(52%) of the title compound as a white solid, mp 195-198° C. dec.

Example 8

(S)-N- 3-3-Fluoro-4-(2H-1,2,3-triazol-2-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide

3-Fluoro-1-(phenylmethoxycarbonylamino)-4-(2H-1,2,3-triazol-2-yl)benzene

A solution of 6.0 g (28.82 mmol) of3-fluoro-1-nitro-4-(2H-1,2,3-triazol-2-yl)benzene in 150 mL ethylacetate and 25 mL methanol was treated with 750 mg of W-2 Raney Nickel.The mixture was hydrogenated on a Paar shaker under 45 psi hydrogenpressure for 24 h. The mixture was filtered through celite and thefiltrate was concentrated in vacuo. The residue was dissolved in 150 mLacetone, treated with 72 mL saturated sodium bicarbonate solution,followed by cooling to 0° C. The mixture was treated with 6.15 g (5.14mL, 36.08 mmol) of benzyl chloroformate, followed by stirring at 0° C.for 1 h, and then warming to ambient temperature for 3 h. The mixturewas diluted with 500 mL water and 400 mL ethyl acetate. The aqueousphase was washed with 250 mL ethyl acetate and the combined organiclayers were extracted with 300 mL saturated NaCl solution. Drying (Na₂SO₄) and concentration in vacuo afforded an amber oil which wasrecrystallized from hot chlorform-hexane to afford 7.52 g (84%) of thetitle compound as a white solid, mp 99.5-101° C.

(R)- 3-3-Fluoro-4-(2H-1,2,3-triazol-2-yl)phenyl!-2-oxo-5-oxazolidinyl!methanol

A solution of 1.0 g (3.20 mmol) of the previous compound in 45 mL THF at-78° C. was treated with 3.52 mL (1.0M, 3.52 mmol) of lithiumbis-(trimethylsilyl)amide in THF, followed by stirring at -78° C. for 30min. The solution was treated with 508 mg (0.50 mL, 3.52 mmol) of(R)-(-)-glycidiyl butyrate followed by stirring at 0° C. for 30 min, andthen to ambient temperature for 18 h. The mixture was diluted with 75 mLethyl acetate and extracted with water (2×75 mL) and saturated NaClsolution (75 mL). Drying (Na₂ SO₄) and concentration in vacuo affordedan amber oil, which was dissolved in 75 ml of methanol and treated with1.0 g of K₂ CO₃ followed by stirring for 2 h. The mixture was filteredand concentrated in vacuo to afford an amber oil which waschromatographed over 50 g of 230-400 mesh silica gel, eluting with 3%(v/v) methanol in dichloromethane. These procedures afforded 446 (50%)of the title compound as a white solid, mp 159-151° C.

(R)- 3-3-Fluoro-4-(2H-1,2,3-triazol-2-yl)phenyl!-2-oxo-5-oxazolidinyl!methylazide

A solution of 350 mg (1.26 mmol) of the previous alcohol and 2 mL oftriethylamine in 8 mL dichloromethane at 0° C. was treated with 362 mg(1.64 mmol) of nosyl chloride, followed by stirring at 0° C. for 30 min,and warming to ambient temperature for 1 h. The mixture was diluted with50 mL dichloromethane and was extracted with water (215.8 g×50 mL).Drying (Na₂ SO₄) and concentration in vacuo afforded 540 mg (92%) of thecorresponding nosylate, which was dissolved in 12 mLN,N-dimethylformamide and treated with 2 g of sodium azide, followed bystirring at ambient temperature for 48 h. The solution was dilutied with125 mL ethyl acetate and extracted with water (5×50 mL). Drying (Na₂SO₄) and concentration in vacuo afforded a yellow solid, which waschromatographed over 50 g of 230-400 mesh silica gel, eluting withdichloromethane and then with 5% (v/v) acetone in dichloromethane. Theseprocedures afforded 333 mg (94%) of the title azide as a faint yellowsolid. ¹ H NMR (CDCl₃) δ 7.87, 7.70, 7.38, 4.84, 4.13, 3.91, 3.75, 3.63.

(S)-N- 3-3-Fluoro-4-(2H-1,2,3-triazol-2-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide

A solution of the previous azide in 50 mL ethyl acetate was treated with500 mg of W-2 Raney nickel followed by hydrogenation on a Paar shakerunder 30 psi of hydrogen for 18 h. The mixture was filtered throughcelite, and the filtrated was concentrated in vacuo. The residue wasdissolved in 8 mL pyridine and treated with 4 mL acetic anhydridefollowed by stirring at ambient temperature for 24 h. The solvents wereremoved under high vacuum (0.2 mm Hg) and the residue was dissolved in75 mL ethyl acetate and extracted with water (2×50 mL) and saturatedNaCl solution (50 mL). Drying (Na₂ SO₄) and concentration in vacuoafforded an amber oil which was subjected to radial chromatography on a4 mm chromatotron plate, eluting with 4% (v/v) methanol indichloromethane. The material obtained was recrystallized from hotchloroform-hexane to afford 164 mg (47%) of the title compound. ¹ H NMR(CDCl₃) δ 7.87, 7.82, 7.70, 7.32, 6.21, 4.83, 4.10, 3.84, 3.68, 2.03.

Example 9

(S)-N- 3-3-Fluoro-4-(3-mercapto-4H-1,2,4-triazol-4-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide

4-(N-Benzylamino)-3-fluoronitrobenzene

A solution of 23.9 g (16.9 mL, 0.15 mol) of 3,4-difluoronitrobenzene and29.1 g (39.2 mL, 0.23 mol) of N, N-diisopropylethylamine in 285 mLacetonitrile was treated with 19.3 g (19.7 mL, 0.18 mol) of benzylamine,followed by warming at reflux for 5 h. The mixture was concentrated invacuo and the residue was dissolved in 200 mL ethyl acetate, followed byextraction with water (3×50 mL). Drying (Na₂ SO₄) and concentration invacuo afforded a yellow solid, which was recrystallized from hot ethylacetate-hexane to afford 32.25 g (87%) of the title compound asyellow-orange needles, mp 97.5-99° C.

4-(N-Benzylbenzyloxycarbonylamino)-1-(benzyloxycarbonylamino)-3-fluorobenzene

A solution of 14.25 g (0.058 mol) of the previous compound in 800 mL THFwas treated with 1.0 g of 5% platinum on carbon, followed byhydrogenation on a Parr shaker under 30 psi hydrogen pressure for 18 h.The mixture was filtered through celite, washing the filter cake withethyl acetate. The filtrate was concentrated in vacuo to afford an oilyresidue which was dissolved in 1.0 L of THF and treated with 15.8 g(16.5 mL, 0.13 mol) of N, N-dimethylaniline. The solution was cooled to0° C. and 21.72 g (18.18 mL, 0.127 mol) of benzyl chloroformate wasadded dropwise over 3 min. The solution was stirred at 0° C. for 30 minand then was allowed to gradually warm to ambient temperature, followedby stirring for 23 h. The solution was concentrated in vacuo and theresidue was dissolved in 1 L of ethyl acetate. The mixture was washedwith 80 mL cold 1N HCl solution, 80 mL water, and 80 mL saturated NaHCO₃solution. The solution was dried (MgSO₄) and concentrated in vacuo toafford an oil which was chromatographed over 500 g of 230-400 meshsilica gel, eluting with 10-15% (v/v) ethyl acetate in hexane. Theseprocedures afforded 12.42 g (44%) of the title compound as a whitesolid, mp 101-102.5° C.

(R)- 3-3-Fluoro-4-(N-benzylbenzyloxycarbonylamino)phenyl!-2-oxo-5-oxazolidinyl!methanol

A solution of 12.42 g (0.026 mol) of the previous compound in 375 mL THFat -78° C. was treated with 16.7 mL (1.6M, 0.027 mol) of n-butyllithiumin hexanes dropwise over 6 min, followed by stirring at -78° C. for 30min. The solution was then treated with 4.6 g (4.5 mL, 0.032 mol) of(R)-(-)-glycidyl butyrate, followed by stirring at -78° C. for 1 h, andwarming to ambient temperature for 20 h. The solution was treated with25 mL saturated ammonium chloride solution, followed by addition of 25mL water and 300 mL ethyl acetate. The aqueous phase was extracted withethyl acetate and the combined organic layers were dried (MgSO₄) andconcentrated in vacuo. The oil obtained was chromatographed over 400 gof 230-400 mesh silica gel, eluting with 1% (v/v) methanol indichloromethane. These procedures afforded 7.56 g (66%) of the titlecompound as a white solid. ¹ H NMR (CDCl₃) δ 7.48, 7.25, 7.07, 6.95,5.15, 4.18, 4.67, 3.91, 3.69.

(S)-N- 3-3-Fluoro-4-(N-benzylbenzyloxycarbonylamino)phenyl!-2-oxo-5-oxazolidinyl!methylacetamide

A solution of 8.23 g (18.3 mmol) of the prevous compound and 3.24 g (4.5mL, 32.0 mmol) of triethylamine in 107 mL dichloromethane at 0° C. wastreated with 5.47 g of nosyl chloride, followed by stirring at 0° C. for4 h. The mixture was diluted with dichloromethane and extracted withwater (2×). Drying (Na₂ SO₄) and concentration in vacuo afforded ayellow foam, which was dissolved in 58 ml isopropyl alcohol, 93 mLacetonitrile, and 116 mL ammonium hydroxide, followed by warming at 40°C. for 18 h. The mixture was cooled, diluted with ethyl acetate andextracted with water (3×) and saturated NaCl solution. Drying (Na₂ SO₄)and concentration in vacuo afforded a yellow foam, which was dissolvedin 200 ml of ethyl acetate and treated with 4.67 g (4.3 mL, 45.75 mmol)of pyridine and 7.24 g (7.4 mL, 91.5 mmol) of acetic anhydride. Thesolution was stirred at ambient temperature for 18 h, followed byextraction with water (3×) and saturated NaCl solution. Drying (Na₂ SO₄)and concentration in vacuo afforded an amber foam, which waschromatographed over 450 g of 230-400 mesh silica gel, eluting with 1%(v/v) methanol in dichloromethane. These procedures afforded 7.04 g(78%) of the title compound as a light yellow rigid foam. HighResolution Mass Spectrum (EI): calcd for C₂₇ H₂₆ FN₃ O₅ : 491.1856.found: 491.1860.

(S)-N- 3- 3-Fluoro-4-aminophenyl!-2-oxo-5-oxazolidinyl!methylacetamide

A solution of 5.6 g (11.4 mmol) of the previous compound in 200 mLethanol was treated with 200 mg of 10% palladium on carbon, followed byhydrogenation on a Parr shaker under 45 psi of hydrogen pressure for 24h. The mixture was filtered through celite, washing the filter cake withmethanol. The filtrate was concentrated in vacuo to afford an off-whitesolid, which was recrystallized from hot ethyl acetate-hexane to afford2.81 g (92%) of the title compound as an off-white solid. ¹ H NMR (DMSO)δ 8.20, 7.29, 6.95, 6.76, 5.00, 4.65, 4.00, 3.63, 3.37, 1.83.

(S)-N- 3-3-Fluoro-4-isothiocyanophenyl!-2-oxo-5-oxazolidinyl!methylacetamide

A solution of 960 mg (4.12 mmol) of 1,1'-thiocarbonyldi-2(1H)-pyridonein 30 mL dichloromethane at 0° C. was treated with 1.0 g (3.74 mmol) ofthe previous compound in one portion. The mixture was stirred at 0° C.for 2.5 h, followed by warming to ambient temperature for 2 h. Themixture was concentrated in vacuo and the solid obtained was trituratedwith 15 mL water. The product was collected by filtration and washedwith a small amount of water, followed by drying overnight in a vacuumoven. These procedures afforded 1.09 g (94%) of the title compound as awhite solid, mp 172.5-176° C.

(S)-N- 3- 3-Fluoro-4-3-mercapto-4H-1,2,4-triazol-4-yl!phenyl!-2-oxo-5-oxazolidinyl!methylacetamide

A solution of 1.11 g (3.59 mmol) of the previous compound in 26 mL THFwas treated with 230 mg (3.77 mmol) of formic hydrazide followed bywarming at 70° C. for 3.5 h. The mixture was cooled, and the precipitatewas collected by filtration and washed with ethyl acetate. The solid wasdried in a vacuum oven at 60° C. to afford 1.2 g of a solid. Of thismaterial, 100 mg (0.27 mmol) was suspended in 2 mL water and treatedwith 0.28 mL (0.97M, 0.27 mmol) of KOH solution, followed by stirringfor 45 min. The solution was then treated with 0.28 mL (1.0N, 0.28 mmol)of HCl solution. The precipitate was collected by filtration and washedwith a small amount of 1N HCl solution. The solid was dried in a vacuumoven at ambient temperature. These procedures afforded 83 mg of thetitle compound as a white solid, mp 269-271° C.

Example 10

(S)-N- 3-3-Fluoro-4-(3-methylthio-4H-1,2,4-triazol-4-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide

A suspension of 200 mg (0.57 mmol) of the compound of Example 9 and 121mg (53 μL, 0.85 mmol) of methyl iodide in 5 mL methanol was treated with53 mg (0.63 mmol) of solid sodium bicarbonate. The mixture was stirredat ambient temperature for 23 h, and the precipitated solid wascollected by filtration, and the filter cake was washed with methanol.The filtrate was concentrated in vacuo to afford a gum which waschromatographed over 25 g of 230-400 mesh silica gel, eluting with 5%(v/v) methanol and 0.5% (v/v) ammonium hydroxide in dichloromethane.These procedures afforded a white solid, which was recrystallized frommethanol to afford 128 mg (61%) of the title compound as a white solid,mp 188.5-190.5° C.

Example 11

(S)-N- 3-3-Fluoro-4-(4H-1,2,4-triazol-4-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide

330 mg (0.938 mmol) of the mercaptan of Example 9 was added to 0.6 mL of20% nitric acid solution, followed by warming on a steam bath for ca. 1min. After this time, an additional 0.6 mL of 20% nitric acid was added,followed by warming on a steam bath for 6-7 min, at which point allsolids had gone into solution. The mixture was cooled to 0° C. andadjusted to pH9 by addition of ammonium hydroxide solution. The mixturewas concentrated in vacuo to afford a brown gummy oil, which waschromatographed over 25 g of 230-400 mesh silica gel, eluting with 5%(v/v) methanol and 0.5% (v/v) ammonium hydroxide in dichloromethane toafford a solid, which was recrystallized from acetonitrile to afford thetitle compound, mp 204.5-206° C.

Example 12

(S)-N- 3-3-Fluoro-4-(1H-pyrrol-1-yl-3-carboxaldehyde)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide

A solution of 2.0 g (7.5 mmol) of the aniline derivative of Example 9and 1.68 g (10.5 mmol) of 2,5-dimethoxy-3-tetrahydrofurancarboxaldehydein 55 mL glacial acetic acid was warmed at reflux for 2 h. The solutionwas cooled and the solvent removed under high vacuum, azeotroping theresidue with toluene to remove the last traces of acetic acid. Theresidue was chromatographed over 300 g of 230-400 mesh silica gel,eluting with dichloromethane and then with 1-3% (v/v) methanol indichloromethane. These procedures afforded 2.21 g of the title compoundas a light yellow amorphous solid. Resolution Mass Spectrum: calcd forC₁₇ H₁₆ FN₃ O₄ : 345.1125. found: 345.1129.

Example 13

(S)-N- 3-3-Fluoro-4-(3-hydroxymethyl-1H-pyrrol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide

A solution of 125 mg (0.36 mmol) of the previous compound in 4 mLmethanol and 2 mL dichloromethane at 0° C. was treated with 7 mg (0.18mmol) of sodium borohydride. The solution was allowed to warm to ambienttemperature for 4 h, followed by dilution with 30 mL dichloromethane andextraction with water. Drying (Na₂ SO₄) and concentration in vacuoafforded a white solid, which was recrystallized from ethylacetate-methanol-hexane. These procedures afforded 106 mg (84%) of thetitle compound as a white solid. High Resolution Mass Spectrum (EI):calcd for C₁₇ H₁₈ FN₃ O₄ : 347.1281. found: 347.1274.

Example 14

(S)-N- 3-3-Fluoro-4-(3-carbomethoxy-1H-pyrrol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide

A solution of 220 mg (0.64 mmol) of the compound of Example 12 in 10 mLof 1:1 acetonitrile-methanol was treated with 164 mg (0.64 mmol) ofsodium cyanide, 1.15 g (13.2 mmol) of activated manganese dioxide, and60 mg (58 μL, 1.0 mmol) of glacial acetic acid. The mixture was stirredat ambient temperature for 36 h, at which point 550 mg (6.32 mmol) ofactivated manganese dioxide and 60 mg (58 μL, 1.0 mmol) of glatialacetic acid were added. The solution was stirred for an additional 24 h,and was filtered through celite, washing the filter cake with methanol.The filtrate was concentrated in vacuo, diluted with ethyl acetate andextracted with water (3×). The organic layer was dried (Na₂ SO₄) andconcentrated in vacuo to afford a pink solid. This material wassubjected to radial chromatography on a 2 mm chromatotron plate, elutingwith dichloromethane and then with 1-2% (v/v) methanol indichloromethane. These procedures afforded 170 mg (71%) of the titlecompound as a white solid. Analysis: calcd for C₁₈ H₁₈ FN₃ O₅ : C,57.60; H, 4.83; N, 11.20. found: C, 57.29; H, 5.19; N, 11.07.

Example 15

(S)-N- 3-3-Fluoro-4-(1H-pyrrol-1-yl-3-carboxaldehyde)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide,methoxime

A solution of 150 mg (0.43 mmol) of the compound of Example 12 in 5 mLof 1:1 methanol-dichloromethane was treated with 44 mg (0.52 mmol) ofmethoxylamine hydrochloride and 36 mg (0.26 mmol) of potassiumcarbonate, followed by stirring at ambient temperature for 18 h. Themixture was diluted with dichloromethane and was extracted with water(3×). Drying (Na₂ SO₄) and concentration in vacuo afforded ared-brown-solid. This material was subjected to radial chromatography ona 2 mm chromatotron plate, eluting with dichloromethane and then with1-2% (v/v) methanol in dichloromethane. These procedures afforded 101 mg(63%) of the title compound as a white solid which was a mixture of E-and Z- double bond stereoisomers. High Resolution Mass Spectrum (EI):calcd for C₁₈ H₁₉ FN₄ O₄ : 374.1390. found: 374.1390.

Example 16

(S)-N- 3-3-Fluoro-4-(3-(hydroxyiminomethyl)-1H-pyrrol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide

A solution of 150 mg (0.43 mmol) of the aldehyde of Example 12 and 36 mg(0.26 mmol) of potassium carbonate in 10 mL of 1:1methanol-dichloromethane was treated with 36 mg (0.52 mmol) ofhydroxylamine hydrochloride, followed by stirring at ambient temperaturefor 48 h. The mixture was diluted with ethyl acetate, extracted withwater (3×), dried (Na₂ SO₄) and concentrated in vacuo to afford anoff-white solid. This material was subjected to radial chromatography ona 2 mm chromatotron plate, eluting with 2-4% (v/v) methanol indichloromethane. These procedures afforded 90 mg (58%) of the titlecompound as a white solid. ¹ H NMR (DMSO) δ 11.07, 10.5, 8.24, 8.01,7.85, 7.70, 7.62, 7.40, 7.30, 7.14, 6.63, 6.48, 4.75, 4.16, 3.77, 3.42,1.83.

Example 17

(S)-N- 3-3-Fluoro-4-(4-acetyl-1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide

(S)-N- 3- 4-Azido-3-fluorophenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide

A solution of 4.0 g (14.96 mmol) of (S)-N- 3-3-Fluoro-4-aminophenyl!-2-oxo-5-oxazolidinyl!methylacetamide fromExample 9 in 40 mL of 6N HCl solution at 0° C. was treated portionwisewith 4.12 g (59.84 mmol) of sodium nitrite, followed by stirring at 0°C. for 2 h. The mixture was then treated in several portions with asolution of 1.94 g (29.92 mmol) of sodium azide and 24.52 g (0.30 mol)of sodium acetate in in 50 mL of water. After addition was complete,solution was extracted with ethyl acetate, and the organic layer wasdried (Na₂ SO₄) and concentrated in vacuo to afford 4.1 g (93%) of thetitle compound as a light yellow solid, sufficiently pure for furtheruse. ¹ H NMR (CDCl₃) δ 8.22, 7.59, 7.33, 4.72, 4.10, 3.72, 3.40, 1.90.

(S)-N- 3-3-Fluoro-4-(4-acetyl-1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazoldinyl!methyl!acetamide

A solution of 500 mg (1.7 mmol) of the previous azide in 25 ml benzenewas treated with 347 mg (5.1 mmol) of 3-butyn-2-one followed by warmingat reflux for 18 h. The mixture was cooled and the 407 mg (66%) of thetitle compound was isolated by filtration of the reaction mixture. HighResolution Mass Spectrum (EI): calcd for C₁₆ H₁₆ FN₅ O₄ : 361.1186.found: 361.1183.

Example 18

(S)-N- 3-3-Fluoro-4-(4-(1-hydroxyethyl)-1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide

A solution of 150 mg (0.40 mmol) of the compound of Example 17 in 10 mL1:1 THF-methanol was treated with 15 mg (0.4 mmol) of sodium borohydridefollowed by stirring at ambient temperature for 18 h. The mixture wasconcentrated in vacuo, dissolved in 1:1 methanol-dichloromethane andfiltered. The filtrate was concentrated in vacuo and the residue wassubjected to radial chromatography on a 2 mm chromatotron plate. Theseprocedures afforded 120 mg (80%) of the title compound as a white solid.Mass Spectrum (EI): m/z 363, 291, 276, 232, 217, 207, 191, 179, 163,148, 135, 123, 85, 56.

Example 19

(S)-N- 3-3-Fluoro-4-(4-(1-hydroxyiminomethyl)-1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide

A solution of 150 mg (0.40 mmol) of the compound of Example 17 in 10 mLof 1:1 THF-methanol was treated with 66 mg (0.96 mmol) of hydroxylaminehydrochloride and 66 mg (0.48 mmol) of potassium carbonate, followed bystirring at ambient temperature for 8 h, and then warming at reflux for2 h. The mixture was concentrated in vacuo, and the residue wassubjected to radial chromatography on a 2 mm chromatotron plate, elutingwith 5% (v/v) methanol in dichloromethane. These procedures afforded 30mg (20%) of the title compound as a white solid. MassSpectrum (EI): m/z376, 332, 318, 287, 274, 245, 220, 202, 187, 175, 163, 149, 139, 82, 56.

Example 20

(S)-N- 3-3-Fluoro-4-(4-carbomethoxy-1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide

A solution 1.0 g (3.4 mmol) of the azide of Example 17 in 50 mL benzenewas treated with 573 mg (6.8 mmol) of methyl propiolate followed bywarming at reflux for 24 h. The mixture was cooled and the productisolated by filtration of the reaction mixture. These proceduresafforded 880 mg of the title compound as a white solid. High ResolutionMass Spectrum (EI): calcd for C₁₆ H₁₆ FN₅ O₅ : 377.1135. found:377.1131.

Example 21

(S)-N- 3-3-Fluoro-4-(1H-1,2,3-triazol-1-yl-4-carboxaldehyde)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide

A solution of 1.70 g (5.8 mmol) of the azide of example 17 in 50 mLbenzene was treated with 4.46 g (34.8 mmol) of 1,1-diethoxy-2-propynefollowed by warming at reflux for 18 h. The solution was treated with1.0 g (7.80 mmol) of 1,1-diethoxy-2-propyne followed by warming atreflux for an additional 3 h. The solution was cooled and concentratedin vacuo to afford an oil which was chromatographed over 200 g of230-400 mesh silica gel, eluting with 2-3% (v/v) methanol indichloromethane to afford 2.0 g (80%) of (S)-N- 3-3-Fluoro-4-(4-(diethoxymethyl)-1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazoldinyl!methyl!acetamideand (S)-N- 3-3-Fluoro-4-(5-(diethoxymethyl)-1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazoldinyl!methyl!acetamideas an inseparable mixture of isomers. Of this material, 410 mg (0.973mmol) was dissolved in 10 mL THF and treated with 1 mL of 1N HClsolution followed by stirring at ambient temperature for 48 h, and thenwarming at reflux for 1 h. The mixture was dissolved in ethyl acetateand extracted with water. Drying (Na₂ SO₄) and concentration in vacuoafforded an oil which was subjected to radial chromatography on a 2 mmchromatotron plate eluting with 7% (v/v) methanol in dichloromethane.The less polar fraction 110 mg (33%)! from the chromatography proved tobe the title compound, isolated as a white solid. ¹ H NMR (CDCl₃) δ8.60, 7.99, 7.85, 7.36, 6.1, 4.86, 4.12, 3.89, 3.72, 2.04.

Example 22

(S)-N- 3-3-Fluoro-4-(4-hydroxymethyl-1H-pyrazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide

Methyl 3-pyrazolecarboxylate hydrochloride

10 mL of methanol at 0° C. was treated dropwise with 1 mL acetylchloride, followed by addition of 2.0 g (17.84 mmol) of4-pyrazolecarboxylic acid, followed by warming the mixture at reflux for18 h. The solution was cooled and concentrated in vacuo to afford 2.6 g(90%) of the title compound as a white solid. ¹ H NMR (CD₃ OD) δ 8.25,3.86.

4-(4-Carbomethoxy-1H-pyrazol-1-yl)-3-Fluoro-1-nitrobenzene

A solution of 2.9 g (17.84 mmol) of the previous compound and 4.93 g(35.68 mmol) of potassium carbonate in 85 mL DMSO was treated with 2.83g (17.84 mmol) of 3,4-difluoronitrobenzene. The solution was warmed at90° C. for 16 h, followed by cooling, dilution with chloroform andextraction with water (5×). Drying (Na₂ SO₄) and concentration in vacuoafforded 4.17 g (88%) of the title compound as an off-white solid. ¹ HNMR (CDCl₃) δ 8.65, 8.28, 8.20, 3.91.

4-(4-Carbomethoxy-1H-pyrazol-1-yl)-3-Fluoro-1-(phenylmethoxycarbonylamino)benzene

A solution of 4.17 g (15.7 mmol) of the previous compound in 200 mL THFwas treated with 1 g of W-2 Raney nickel, followed by hydrogenation on aParr shaker under 45 psi hydrogen pressure for 18 h. The mixture wasfiltered through celite, and the filtrate concentrated in vacuo toafford an off-white solid, which was dissolved in 30 mL THF and 5 mLacetone and treated with 34 mL saturated sodium bicarbonate solution,followed by cooling to 0° C. and and addition of 3.21 g (2.69 mL, 18.8mmol) of benzyl chloroformate. The solution was stirred at 0° C. for 1h, and then was allowed to warm to ambient temperature for 18 h. Themixture was concentrated in vacuo, and the resulting aqueous layer wasextracted with ethyl acetate (3×). The organic layer was dried (Na₂ SO₄)and concentrated in vacuo to afford 3.1 g (53%) of the title compound asa white solid. ¹ H NMR (CDCl₃) δ 8.41, 8.10, 7.79, 7.64, 7.40, 7.10,6.88, 5.23, 3.88.

4-(4-hydroxymethyl-1H-pyrazol-1-yl)-3-Fluoro-1-(phenylmethoxycarbonylamino)benzene

A solution of 3.0 g (8.13 mmol) of the previous compound in 20 mLanhydrous THF was treated with 1.42 g (65.04 mmmol) of lithiumborohydride, followed by stirring at ambient temperature for 18 h. Thesolution was treated with 5 mL saturated sodium bicarbonate solution,followed by concentration in vacuo. The mixture was diluted with ethylacetate and extracted with water. Drying (Na₂ SO₄) and concentration invacuo afforded a residue which was chromatographed over 150 g of 230-400mesh silica gel, eluting with 2% (v/v) methanol in dichloromethane.These procedures afforded 1.63 g (59%) of the title compound as a whitesolid. High Resolution Mass Spectrum (EI): calcd for C₁₈ H₁₆ FN₃ O₃ :341.1176. found: 341.1180.

4-(4-(tetrahydropyran-2-yl)oxymethyl!-1H-pyrazol-1-yl)-3-Fluoro-1-(phenylmethoxycarbonylamino)benzene

A solution of 1.63 g (4.77 mmol) of the previous compound in 30 mLdichloromethane was treated with 400 mg (4.75 mmol) of dihydropyran and10 mg of p-toluenesulfonic acid. The solution was stirred at ambienttemperature for 18 h, followed by extraction with 30 mL saturated sodiumbicarbonate solution and water (30 mL). Drying (Na₂ SO₄) andconcentration in vacuo afforded a solid which was chromatographed over85 g of 230-400 mesh silica gel eluting with 20% (v/v) ethyl acetate inhexane. These procedures afforded 2.0 g (99%) of the title compound as awhite solid. High Resolution Mass Spectrum (EI): calcd for C₂₃ H₂₄ FN₃O₄ : 425.1751. found: 425.1747.

(R)- 3- 3-Fluoro-4-(4-(tetrahydropyran-2-yl)oxymethyl!-1H-pyrazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methanol

A solution of 1.43 g (3.36 mmol) of the previous compound in 10 mL THFat -78° C. was treated with 3.7 mL (1.0M, 3.7 mmol) of lithiumbis(trimethylsilyl)amide in THF, followed by stirring at 78° C. for 30min. The solution was then treated with 533 mg (0.52 mL, 3.7 mmol) of(R)-(-)-glycidyl butyrate followed by stirring at 78° C. for 30 min,warming to 0° C. for 30 min, and then gradual warming to ambienttemperature for 18 h. The solution was treated with 1 mL saturatedammonium chloride solution and diluted with ethyl acetate. The mixturewas extracted with with water, dried (Na₂ SO₄) and concentrated invacuo. The residue was chromatographed over 70 g of 230-400 mesh silicagel, eluting with 2% (v/v) methanol in dichloromethane. These proceduresafforded 910 mg (70%) of the title compound as a white solid. Highresolution Mass Spectrum (EI): calcd for C₁₉ H₂₂ FN₃ O₅ : 391.1543.found: 391.1542.

(R)- 3- 3-Fluoro-4-(4-(tetrahydropyran-2-yl)oxymethyl!-1H-pyrazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methanesulfonyloxymethane

A solution 0.820 mg (2.1 mmol) of the previous compound and 318 mg (3.15mmol) triethylamine in 25 mL of dichloromethane at 0° C. was treatedwith 360 mg (2.62 mmol) of methanesulfonyl chloride. The solution wasstirred at 0° C. for 1 h. The solution was diluted with dichloromethaneand extracted with water. Drying (Na₂ SO₄) and concentration in vacuoafforded 986 mg (99%) of the title compound as a white solid. ¹ H NMR(CDCl₃) δ 7.95, 7.92, 7.74, 7.25, 4.97, 4.75, 4.50, 4.20, 4.01, 3.93,3.59, 3.12, 1.85, 1.74, 1.56.

(R)- 3- 3-Fluoro-4-(4-(tetrahydropyran-2-yl)oxymethyl!-1H-pyrazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methylazide

A solution of 986 mg (2.1 mmol) of the previous compound and 683 mg(10.5 mmol) of sodium azide in 20 mL DMF was warmed at 60° C. for 18 h,followed by dilution with ethyl acetate and extraction with water.Drying (Na₂ SO₄) and concentration in vacuo afforded 874 mg (99%) of thetitle compound as a white solid. ¹ H NMR (CDCl₃) δ 7.98, 7.87, 7.74,7.23, 4.82, 4.72, 4.50, 4.11, 3.90, 3.73, 3.61, 3.55, 1.81, 1.73, 1.58.

(S)-N- 3- 3-Fluoro-4-(4-(tetrahydropyran-2-yl)oxymethyl!-1H-pyrazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide

A solution of 874 mg (2.1 mmol) of the previous compound in 15 mL ethylacetate was treated 200 mg of 10% palladium on carbon, followed byhydrogenation at one atmosphere for 1.5 h. The solution was filteredthrough celite and the filtrate concentrated in vacuo to afford a brownsolid, which was dissolved in 3 mL pyridine and treated with 428 mg (4.2mmol) of acetic anhydride, followed by stirring at ambient temperaturefor 18 h. The solution was diluted with ethyl acetate and extracted withwater. Drying (Na₂ SO₄) and concentration in vacuo afforded a solidwhich was chromatographed over 50 g of 230-400 mesh silica gel elutingwith 1-2% (v/v) methanol in dichloromethane. These procedures afforded626 mg (69%) of the title compound as a white solid. High ResolutionMass Spectrum (EI): calcd for C₂₁ H₂₅ FN₄ O₅ : 432.1809. found:432.1811.

(S)-N- 3-3-Fluoro-4-(4-hydroxymethyl-1H-pyrazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide

A solution of 300 mg (0.693 mmol) of the previous compound in 15 mLmethanol was treated with 40 mg of p-toluenesulfonic acid, followed bystirring at ambient temperature for 18 h. The mixture was concentratedin vacuo and the residue dissolved in ethyl acetate and extracted withsaturated sodium bicarbonate solution and water. Drying (Na₂ SO₄) andconcentration in vacuo afforded 140 mg (58%) of the title compound as awhite solid. High Resolution Mass Spectrum (EI): calcd for C₁₆ H₁₇ FN₄O₄ : 349.1312. found: 349.1321.

Example 23

(S)-N- 3- 3-Fluoro-4-3-(2-carboethoxyvinyl)-1H-pyrrol-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide

A solution of 805 mg (3.19 mmol) of diisopropylethoxycarbonylmethylphosphonate in 7 mL THF at 0° C. was treated with3.19 mL (1.0M, 3.19 mmol) of potassium tert-butoxide in THF solution,followed by warming to ambient temperature for 1 h. The solution wascooled to -78° C. and treated via cannula with a solution of 500 mg(1.45 mmol) of the compound of Example 12 in 4 mL THF. The solution wasstirred at -78° C. for 30 min, followed by warming to ambienttemperature for 2 h. The solution was quenched by addition of 1 mLsaturated ammonium chloride solution followed by dilution with ethylacetate and extraction with water. Drying (Na₂ SO₄) and concentration invacuo afforded a yellow solid, which was chromatographed over 100 g of230-400 mesh silica gel, eluting with 1-2% (v/v) methanol indichloromethane. These procedures afforded 497 mg (83%) of the titlecompound as a light yellow solid. ¹ H NMR (CDCl₃) δ 7.65, 7.37, 7.27,7.20, 6.97, 6.56, 6.17, 6.02, 4.82, 4.24, 4.08, 3.83, 3.70, 2.04, 1.33.

Example 24

(S)-N- 3- 3-Fluoro-4-3-(2-carboethoxyethyl)-1H-pyrrol-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide

A solution of 150 mg (0.36 mmol) of the compound of Example 23 and 54 mg(0.54 mmol) of copper I! chloride in 15 mL 1:1 Methanol-THF at 0° C. wastreated with 136 mg (3.6 mmol) of sodium borohydride. The solution wasstirred at 0° C. for 30 min and then warmed to ambient temperature for 1h. The solution was treated with 2 mL saturated ammonium chloridesolution, followed by filtration through celite. The filtrate wasconcentrated in vacuo and the residue was diluted with ethyl acetate andextracted with water (3×). Drying (Na₂ SO₄) and concentration in vacuoafforded 150 mg (99%) of the title compound as a white solid. ¹ H NMR(CDCl₃) δ 7.60, 7.34, 7.33, 6.91, 6.81, 6.21, 5.97, 4.81, 4.15, 4.08,3.82, 3.72, 3.65, 2.87, 2.62, 2.04, 1.26.

Example 25

(S)-N- 3- 3-Fluoro-4-3-(3-hydroxypropyl)-1H-pyrrol-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide

A solution of 275 mg (0.66 mmol) of the compound of Example 24 in 15 mLTHF was treated with 287 mg (13.2 mmol) of lithium borohydride followedby stirring at ambient temperature for 18 h. The solution was treatedwith 1 mL of saturated ammonium chloride solution, diluted with ethylacetate, and extracted with water (3×). Drying (Na₂ SO₄) andconcentration in vacuo afforded an oil, which was chromatographed over20 g of 230-400 mesh silica gel eluting with 2-4% (v/v) methanol indichloromethane. These procedures afforded 96 mg (39%) of the titlecompound as a white solid. ¹ H NMR (CDCl₃) δ 7.74, 7.66, 7.38, 7.27,7.18, 6.95, 6.61, 5.98, 4.82, 4.37, 4.27, 4.09, 3.83, 3.68, 2.88, 2.82,2.62, 2.04, 1.79.

Example 26

(S)-N- 3- 3-Fluoro-4-3-(3-methanesulfonylaminopropyl)-1H-pyrrol-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide

A solution of 100 mg (0.266 mmol) of the compound of Example 25(previously dried at 60° C. under 0.1 mmHg for 18 h prior to use) and 88mg (120 μL, 0.88 mmol) of triethylamine in 2 mL dichloromethane at 0° C.was treated with 85 mg (58 μL, 0.73 mmol) of methanesulfonyl chloride,followed by stirring at 0° C. for 30 min. The solution was diluted withdichloromethane and extracted with water (2×) and saturated sodiumbicarbonate solution. Drying (Na₂ SO₄) and concentration in vacuoafforded a solid which was dissolved in 2 mL DMF and treated via cannulato a 0° C. solution of 38 mg (0.40 mmol) of methanesulfonamide in 2 mLDMF which had been previously treated with 10 mg (17 mg of 60% in oil,0.43 mmol) of sodium hydride. The solution was then warmed at 60° C. for18 h. The solution was cooled and the DMF removed in vacuo, and theresidue was dissolved in ethyl acetate and extracted with water (2×).Drying (Na₂ SO₄) and concentration in vacuo afforded a solid which wassubjected to radial chromatography on a 2 mm chromatotron plate, elutingwith 1-4% (v/v) methanol in dichloromethane. These procedures afforded31 mg (26%) of the title compound as a white solid. ¹ H NMR (CDCl₃) δ7.61, 7.56, 7.35, 7.23, 6.92, 6.81, 6.19, 6.06, 4.81, 4.29, 4.07, 3.82,3.67, 3.22, 2.95, 2.62, 2.04, 1.90. ##STR5##

What is claimed is:
 1. A compound structurally represented by Formula Ior pharmaceutically acceptable salts thereof wherein:Q is ahetero-aromatic 5-member ring bound to the aromatic ring of I at thenitrogen of the structures i, ii, iii, iv, v, vi, vii, viii, or ix:##STR6## or alternatively Q can be a benzoannulated hetero-aromatic5-member ring bound to the aromatic ring of I at the nitrogen of thestructures x, xi, xii, or xiii; ##STR7## R¹ is independently (a) H,(b)--OCH₃, (c) F, or (d) Cl; R² is(a) hydrogen, (b) C₁ -C₈ alkyl,optionally substituted with one or more F, Cl, hydroxy, C₁ -C₈ alkoxy,or C₁ -C₈ acyloxy, (c) C₃ -C₆ cycloalkyl, (d) amino, (e) C₁ -C₈alkylamino, (f) C₁ -C₈ dialkylamino, or (g) C₁ -C₈ alkoxy; R³ is eachindependently selected from(a) H, (b) F, Cl, Br, (c) --OR⁴, (d) --SR⁴,(e) --S(O)_(n) R⁴ (n is 1 or 2), (f) --CN, (g) --O₂ CR⁴, (h) --NHCOR⁴,(i) --NHCO₂ R⁴, (j) --NHSO₂ R⁴, (k) --CO₂ R⁴, (l) --CON(R⁴)₂, (m)--COR⁴, (n) C₁ -C₈ straight or branched chain alkyl or C₃ -C₈cycloalkyl, optionally substituted with one or more of (a)-(m), (o)Phenyl, optionally substituted with one or more of the preceding groupslisted under (a)-(n), (p) --CH═CHCO₂ Et, or (q) --C(═NR₅)R₆, wherein R₅is --OH or OCH₃, wherein R₆ is H or CH₃ ; and R⁴ is(a) H, (b) C₁ -C₆straight or branched chain alkyl or C₃ -C₈ cycloalkyl, optionallysubstituted with one or more fluorine, chlorine, hydroxy, C₁ -C₄ alkoxy,C₁ -C₄ acyl, C₁ -C₄ acyloxy, or O₂ CCH₂ N(CH₃)₂, or (c) Phenyl,optionally substituted with one or more of fluorine, chlorine, C₁ -C₄straight or branched chain alkyl, hydroxy, C₁ -C₄ alkoxy, C₁ -C₄ acyl,C₁ -C₄ acyloxy, or O₂ CCH₂ N(CH₃)₂.
 2. The compound of claim 1 wherein Qis i.
 3. The compound of claim 1 wherein Q is ii.
 4. The compound ofclaim 1 wherein Q is iii.
 5. The compound of claim 1 wherein Q is iv. 6.The compound of claim 1 wherein Q is v.
 7. The compound of claim 1wherein Q is vi.
 8. The compound of claim 1 wherein Q is vii.
 9. Thecompound of claim 1 wherein Q is viii.
 10. The compound of claim 1wherein Q is ix.
 11. The compound of claim 1 wherein R¹ is F.
 12. Thecompound of claim 1 wherein R¹ is H.
 13. The compound of claim 1 whereinR² is methyl, dichloromethyl, methoxy, or hydrogen.
 14. The compound ofclaim 1 wherein R³ is hydrogen, C₁ -C₈ alkylhydroxy, C₁ -C₈ alkyl or C₁-C₄ alkoxycarbonyl.
 15. A compound of claim 1 which is(a) (S)-N- 3-3-Fluoro-4-(1H-pyrrol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(b) (S)-N- 3-3-Fluoro-4-(3-carbomethoxy-1H-pyrrol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(c) (S)-N- 3-3-Fluoro-4-(1H-pyrrol-1-yl-3-carboxaldehyde)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(d) (S)-N- 3-3-Fluoro-4-(3-(hydroxyiminomethyl)-1H-pyrrol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(e) (S)-N- 3-3-Fluoro-4-(3-(methoxyiminomethyl)-1H-pyrrol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(f) (S)-N- 3-3-Fluoro-4-(3-hydroxymethyl-1H-pyrrol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(g) (S)-N- 3- 3-Fluoro-4-3-(2-carboethoxyvinyl)-1H-pyrrol-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(h) (S)-N- 3- 3-Fluoro-4-3-(2-carboethoxyethyl)-1H-pyrrol-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(i) (S)-N- 3- 3-Fluoro-4-3-(3-hydroxypropyl)-1H-pyrrol-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(j) (S)-N- 3- 3-Fluoro-4-3-(3-methanesulfonylaminopropyl)-1H-pyrrol-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(k) (S)-N- 3-3-Fluoro-4-(1H-imidazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(l) (S)-N- 3-3-Fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(m) (S)-N- 3-3-Fluoro-4-(4-ethyl-1H-imidazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(n) (S)-N- 3- 3-Fluoro-4-4-(carbomethoxy)-1H-imidazol-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(o) (S)-N- 3- 3-Fluoro-4-4-(hydroxymethyl)-1H-imidazol-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(p) (S)-N- 3- 3-Fluoro-4-4-(2-hydroxyethyl)-1H-imidazol-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(q) (S)-N- 3- 3-Fluoro-4-1H-imidazol-1-yl-4-carboxaldehyde!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(r) (S)-N- 3- 3-Fluoro-4-3-(hydroxyiminomethyl)-1H-imidazol-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(s) (S)-N- 3- 3-Fluoro-4-3-(methoxyiminomethyl)-1H-imidazol-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(t) (S)-N- 3-3-Fluoro-4-(1H-pyrazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(u) (S)-N- 3-3-Fluoro-4-(4-methyl-1H-pyrazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(v) (S)-N- 3- 3-Fluoro-4-3-(hydroxymethyl)-1H-pyrazol-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(w) (S)-N- 3- 3-Fluoro-4-3-(carbomethoxy)-1H-pyrazol-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(x) (S)-N- 3-3-Fluoro-4-(1H-pyrazol-1-yl-3-carboxaldehyde)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(y) (S)-N- 3-3-Fluoro-4-(3-(hydroxyiminomethyl)-1H-pyrazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(z) (S)-N- 3-3-Fluoro-4-(3-(methoxyiminomethyl)-1H-pyrazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(aa) (S)-N- 3- 3-Fluoro-4-4-(hydroxymethyl)-1H-pyrazol-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(bb) (S)-N- 3- 3-Fluoro-4-4-(carbomethoxy)-1H-pyrazol-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(cc) (S)-N- 3-3-Fluoro-4-(1H-pyrazol-1-yl-4-carboxaldehyde)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(dd) (S)-N- 3-3-Fluoro-4-(4-(hydroxyiminomethyl)-1H-pyrazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(ee) (S)-N- 3-3-Fluoro-4-(4-(methoxyiminomethyl)-1H-pyrazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(ff) (S)-N- 3-3-Fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(gg) (S)-N- 3- 3-Fluoro-4-3-mercapto-4H-1,2,4-triazol-4-yl!phenyl!-2-oxo-5-oxazolidinyl!methylacetamide;(hh) (S)-N- 3- 3-Fluoro-4-3-methylthio-4H-1,2,4-triazol-4-yl!phenyl!-2-oxo-5-oxazolidinyl!methylacetamide;(ii) (S)-N- 3- 3-Fluoro-4-4H-1,2,4-triazol-4-yl!phenyl!-2-oxo-5-oxazolidinyl!methylacetamide; (jj)(S)-N- 3-3-Fluoro-4-(1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(kk) (S)-N- 3-3-Fluoro-4-(4-carbomethoxy-1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(ll) (S)-N- 3-3-Fluoro-4-(4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(mm) (S)-N- 3-3-Fluoro-4-(4-(1-hydroxyethyl)-1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(nn) (S)-N- 3-3-Fluoro-4-(1H-1,2,3-triazol-1-yl-4-carboxaldehyde)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(oo) (S)-N- 3-3-Fluoro-4-(4-(hydroxyiminomethyl)-1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide,oxime; (pp) (S)-N- 3-3-Fluoro-4-(4-(methoxyiminomethyl)-1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(qq) (S)-N- 3-3-Fluoro-4-(4-acetyl-1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(rr) (S)-N- 3-3-Fluoro-4-(4-(1-hydroxyiminoethyl)-1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(ss) (S)-N- 3-3-Fluoro-4-(4-(1-methoxyiminoethyl)-1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(tt) (S)-N- 3-3-Fluoro-4-(2H-1,2,3-triazol-2-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(uu) (S)-N- 3-3-Fluoro-4-(1H-1,2,3,4-tetrazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(vv) (S)-N- 3-3-Fluoro-4-(2H-1,2,3,4-tetrazol-2-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(ww) (S)-N- 3-3-Fluoro-4-(1H-indol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(xx) (S)-N- 3-3-Fluoro-4-(7-aza-1H-indol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(yy) (S)-N- 3-3-Fluoro-4-(1H-benzimidazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(zz) (S)-N- 3-3-Fluoro-4-(1H-indazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(aaa) (S)-N- 3-3-Fluoro-4-(1H-benzotriazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(bbb) (S)-N- 3-3-Fluoro-4-(1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!-2,2-dichloroacetamide;or (ccc) (S)-N- 3- 3-Fluoro-4-(1H-1,2,3-triazolo4,5b!-pyridin-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide.
 16. Acompound of 1 which is(a) (S)-N- 3-3-Fluoro-4-(1H-pyrrol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(b) (S)-N- 3-3-Fluoro-4-(3-carbomethoxy-1H-pyrrol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(c) (S)-N- 3-3-Fluoro-4-(1H-pyrrol-1-yl-3-carboxaldehyde)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(d) (S)-N- 3-3-Fluoro-4-(3-(hydroxyiminomethyl)-1H-pyrrol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(e) (S)-N- 3-3-Fluoro-4-(3-(methoxyiminomethyl)-1H-pyrrol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(f) (S)-N- 3-3-Fluoro-4-(3-hydroxymethyl-1H-pyrrol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(g) (S)-N- 3- 3-Fluoro-4-3-(2-carboethoxyvinyl)-1H-pyrrol-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(h) (S)-N- 3- 3-Fluoro-4-3-(2-carboethoxyethyl)-1H-pyrrol-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(i) (S)-N- 3- 3-Fluoro-4-3-(3-hydroxypropyl)-1H-pyrrol-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(j) (S)-N- 3- 3-Fluoro-4-3-(3-methanesulfonylaminopropyl)-1H-pyrrol-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(k) (S)-N- 3-3-Fluoro-4-(1H-imidazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(l) (S)-N- 3-3-Fluoro-4-(1H-pyrazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(m) (S)-N- 3- 3-Fluoro-4-4-(hydroxymethyl)-1H-pyrazol-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(n) (S)-N- 3-3-Fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(o) (S)-N- 3- 3-Fluoro-4-3-mercapto-4H-1,2,4-triazol-4-yl!phenyl!-2-oxo-5-oxazolidinyl!methylacetamide;(p) (S)-N- 3- 3-Fluoro-4-3-methylthio-4H-1,2,4-triazol-4-yl!phenyl!-2-oxo-5-oxazolidinyl!methylacetamide;(q) (S)-N- 3- 3-Fluoro-4-4H-1,2,4-triazol-4-yl!phenyl!-2-oxo-5-oxazolidinyl!methylacetamide; (r)(S)-N- 3-3-Fluoro-4-(1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(s) (S)-N- 3-3-Fluoro-4-(4-carbomethoxy-1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(t) (S)-N- 3-3-Fluoro-4-(4-(1-hydroxyethyl)-1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(u) (S)-N- 3-3-Fluoro-4-(1H-1,2,3-triazol-1-yl-4-carboxaldehyde)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(v) (S)-N- 3-3-Fluoro-4-(4-(hydroxyiminomethyl)-1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(w) (S)-N- 3-3-Fluoro-4-(4-acetyl-1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(x) (S)-N- 3-3-Fluoro-4-(2H-1,2,3-triazol-2-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(y) (S)-N- 3-3-Fluoro-4-(1H-indol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;or (z) (S)-N- 3-3-Fluoro-4-(1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!-2,2-dichloroacetamide.17. A compound of 1 which is(a) (S)-N- 3-3-Fluoro-4-(1H-pyrrol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(b) (S)-N- 3-3-Fluoro-4-(3-carbomethoxy-1H-pyrrol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(c) (S)-N- 3-3-Fluoro-4-(3-(hydroxyiminomethyl)-1H-pyrrol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(d) (S)-N- 3-3-Fluoro-4-(3-(methoxyiminomethyl)-1H-pyrrol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(e) (S)-N- 3- 3-Fluoro-4-3-(2-carboethoxyethyl)-1H-pyrrol-1-yl!phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(f) (S)-N- 3-3-Fluoro-4-(1H-imidazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(g) (S)-N- 3-3-Fluoro-4-(1H-pyrazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(h) (S)-N- 3-3-Fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(i) (S)-N- 3-3-Fluoro-4-(1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(j) (S)-N- 3-3-Fluoro-4-(4-carbomethoxy-1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;(k) (S)-N- 3-3-Fluoro-4-(4-acetyl-1H-1,2,3-triazol-1-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide;or (l) (S)-N- 3-3-Fluoro-4-(2H-1,2,3-triazol-2-yl)phenyl!-2-oxo-5-oxazolidinyl!methyl!acetamide.18. A method for treating microbial infections in patients sufferingtherefrom comprising administering an antibacterially effective amountof a compound of Formula I.
 19. The method of claim 9 wherein theantibacterially effective amount is from about 0.1 to about 100 mg/kg ofbody weight/day.